1
|
Pellegrino B, Tommasi C, Serra O, Gori S, Cretella E, Ambroggi M, Frassoldati A, Bisagni G, Casarini C, Bria E, Carbognin L, Fiorio E, Mura A, Zamagni C, Gianni L, Zambelli A, Montemurro F, Tognetto M, Todeschini R, Missale G, Campanini N, Silini EM, Maglietta G, Musolino A. Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016). J Immunother Cancer 2023; 11:e007667. [PMID: 38016718 PMCID: PMC10685938 DOI: 10.1136/jitc-2023-007667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/06/2023] [Indexed: 11/30/2023] Open
Abstract
BACKGROUND It is possible to induce immunomodulation in HER2-positive breast cancer (BC) by modifying the route of administration of trastuzumab. METHODS In this multicenter randomized phase II trial, all enrolled patients (pts) with T2-T4d HER2-positive BC received 3 cycles of neoadjuvant treatment (NAT) with fluorouracil, epirubicin and cyclophosphamide every 3 weeks (q21), followed by docetaxel/pertuzumab plus intravenous trastuzumab (arm A) or, docetaxel/pertuzumab plus subcutaneous (SC) trastuzumab (arm B) q21x4 cycles. After surgical operation, each pt was treated with trastuzumab q21x14 cycles using the same SC or intravenous formulation of NAT. Primary endpoint was the proportion of subjects with high stromal tumor-infiltrating lymphocytes (sTILs) in postneoadjuvant residual disease (RD). RESULTS Sixty-three pts (31 (arm A) and 32 (arm B)) were enrolled. Pathological complete response was obtained by 20/31 pts (64.5%; 95% CI 45.4% to 80.1%) in arm A and 19/32 pts (59.4%; 95% CI 40.1% to 76.3%) in arm B. High sTILs were observed in 27% and 46% of postneoadjuvant residual tumors in arms A and B, respectively. CD8+ T cells increased significantly in RDs of both arms (p=0.014 and 0.002 for arm A and B, respectively), whereas a significant decline in the level of CD4+ FoxP3+ regulatory T cells was observed only in arm B (p=0.016). A significant upregulation of PD-1 on sTILs was found in RD of pts enrolled in arm B (p=0.012), while programmed death-ligand 1 (PD-L1) was significantly overexpressed in residual tumors of arm A (p=0.02). A strong negative correlation was reported in arm B between expression of PD-L1 on pretreatment sTILs and CD3 expression on sTILs in RD (τ: -0.73). Grade≥3 AE incidence rates were similar between the two arms. CONCLUSIONS SC trastuzumab induced relevant sTILs enrichment, with favorable variations of immune parameters in HER2-positive BC pts with RD after NAT. Novel immunotherapy strategies should be tested to achieve SC-specific, antitumor immune response. TRIAL REGISTRATION NUMBER NCT03144947, and EudraCT number: 2016-000435-41.
Collapse
Affiliation(s)
- Benedetta Pellegrino
- Department of Medicine and Surgery, University of Parma, Parma, Italy
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - Chiara Tommasi
- Department of Medicine and Surgery, University of Parma, Parma, Italy
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - Olga Serra
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - Stefania Gori
- Medical Oncology Unit, Ospedale Sacro Cuore-Don Calabria-Negrar (VR), negrar, Italy
| | | | - Massimo Ambroggi
- Medical Oncology, Hospital of Piacenza, Piacenza, Emilia-Romagna, Italy
| | - Antonio Frassoldati
- Specialist Medical Department, University Hospital Arcispedale Sant'Anna of Ferrara, Cona, Emilia-Romagna, Italy
| | - Giancarlo Bisagni
- Medical Oncology Unit, Azienda Unità Sanitaria Locale-IRCCS Tecnologie Avanzate e Modelli Assistenziali in Oncologia di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy
| | - Chiara Casarini
- Medical Oncology Unit, Ospedale di Sassuolo, Sassuolo, Modena, Italy
| | - Emilio Bria
- Facolta di Medicina e Chirurgia, Universita Cattolica del Sacro Cuore, Roma, Lazio, Italy
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Roma, Italy
| | - Luisa Carbognin
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Roma, Italy
- Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - Elena Fiorio
- Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - Antonella Mura
- Department of Medical Oncology, Azienda USL Bologna, Bologna, Italy
| | - Claudio Zamagni
- Department of Oncology and Hematology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Emilia-Romagna, Italy
| | - Lorenzo Gianni
- Oncology Department, Infermi Hospital, AUSL della Romagna, Rimini, Italy
| | - Alberto Zambelli
- Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy
| | - Filippo Montemurro
- Department of Oncology and Hematology, Candiolo Cancer Institute, Candiolo, Italy
| | | | | | - Gabriele Missale
- Medicine and Surgery, Università degli Studi di Parma, Parma, Italy
| | | | | | | | - Antonino Musolino
- Department of Medicine and Surgery, University of Parma, Parma, Italy
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| |
Collapse
|
2
|
Hansen CJ, Bolton S, Sulaiman AH, Duling S, Bagenal F, Brennan M, Connerney J, Clark G, Lunine J, Levin S, Kurth W, Mura A, Paranicas C, Tosi F, Withers P. Juno's Close Encounter With Ganymede-An Overview. Geophys Res Lett 2022; 49:e2022GL099285. [PMID: 37034391 PMCID: PMC10078441 DOI: 10.1029/2022gl099285] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 05/20/2022] [Accepted: 05/28/2022] [Indexed: 06/19/2023]
Abstract
The Juno spacecraft has been in orbit around Jupiter since 2016. Two flybys of Ganymede were executed in 2021, opportunities realized by evolution of Juno's polar orbit over the intervening 5 years. The geometry of the close flyby just prior to the 34th perijove pass by Jupiter brought the spacecraft inside Ganymede's unique magnetosphere. Juno's payload, designed to study Jupiter's magnetosphere, had ample dynamic range to study Ganymede's magnetosphere. The Juno radio system was used both for gravity measurements and for study of Ganymede's ionosphere. Remote sensing of Ganymede returned new results on geology, surface composition, and thermal properties of the surface and subsurface.
Collapse
Affiliation(s)
| | - S. Bolton
- Southwest Research InstituteSan AntonioTXUSA
| | - A. H. Sulaiman
- Department of Physics and AstronomyUniversity of IowaIowa CityIAUSA
| | | | - F. Bagenal
- Laboratory for Atmospheric and Space PhysicsUniversity of ColoradoBoulderCOUSA
| | | | | | - G. Clark
- Johns Hopkins Applied Physics LaboratoryLaurelMDUSA
| | | | - S. Levin
- Jet Propulsion LaboratoryPasadenaCAUSA
| | - W. Kurth
- Department of Physics and AstronomyUniversity of IowaIowa CityIAUSA
| | - A. Mura
- Istituto Nazionale di AstroFisica – Istituto di Astrofisica e Planetologia Spaziali (INAF‐IAPS)RomeItaly
| | - C. Paranicas
- Johns Hopkins Applied Physics LaboratoryLaurelMDUSA
| | - F. Tosi
- Istituto Nazionale di AstroFisica – Istituto di Astrofisica e Planetologia Spaziali (INAF‐IAPS)RomeItaly
| | | |
Collapse
|
3
|
Persson M, Aizawa S, André N, Barabash S, Saito Y, Harada Y, Heyner D, Orsini S, Fedorov A, Mazelle C, Futaana Y, Hadid LZ, Volwerk M, Collinson G, Sanchez-Cano B, Barthe A, Penou E, Yokota S, Génot V, Sauvaud JA, Delcourt D, Fraenz M, Modolo R, Milillo A, Auster HU, Richter I, Mieth JZD, Louarn P, Owen CJ, Horbury TS, Asamura K, Matsuda S, Nilsson H, Wieser M, Alberti T, Varsani A, Mangano V, Mura A, Lichtenegger H, Laky G, Jeszenszky H, Masunaga K, Signoles C, Rojo M, Murakami G. BepiColombo mission confirms stagnation region of Venus and reveals its large extent. Nat Commun 2022; 13:7743. [PMID: 36522338 PMCID: PMC9755131 DOI: 10.1038/s41467-022-35061-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 11/16/2022] [Indexed: 12/23/2022] Open
Abstract
The second Venus flyby of the BepiColombo mission offer a unique opportunity to make a complete tour of one of the few gas-dynamics dominated interaction regions between the supersonic solar wind and a Solar System object. The spacecraft pass through the full Venusian magnetosheath following the plasma streamlines, and cross the subsolar stagnation region during very stable solar wind conditions as observed upstream by the neighboring Solar Orbiter mission. These rare multipoint synergistic observations and stable conditions experimentally confirm what was previously predicted for the barely-explored stagnation region close to solar minimum. Here, we show that this region has a large extend, up to an altitude of 1900 km, and the estimated low energy transfer near the subsolar point confirm that the atmosphere of Venus, despite being non-magnetized and less conductive due to lower ultraviolet flux at solar minimum, is capable of withstanding the solar wind under low dynamic pressure.
Collapse
Affiliation(s)
- M. Persson
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - S. Aizawa
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - N. André
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - S. Barabash
- grid.425140.60000 0001 0706 1867Swedish Institute of Space Physics, Kiruna, Sweden
| | - Y. Saito
- grid.62167.340000 0001 2220 7916Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Kyoto, Japan
| | - Y. Harada
- grid.258799.80000 0004 0372 2033Department of Geophysics, Graduate School of Science, Kyoto University, Kyoto, Japan
| | - D. Heyner
- grid.6738.a0000 0001 1090 0254Institute for Geophysics and Extraterrestrial Physics, Technische Universität Braunschweig, Braunschweig, Germany
| | - S. Orsini
- grid.4293.c0000 0004 1792 8585Institute of Space Astrophysics and Planetology, Istituto Nazionale di Astrofisica, Rome, Italy
| | - A. Fedorov
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - C. Mazelle
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - Y. Futaana
- grid.425140.60000 0001 0706 1867Swedish Institute of Space Physics, Kiruna, Sweden
| | - L. Z. Hadid
- grid.508893.fLaboratoire de Physique des Plasmas (LPP), Centre National de la Recherche Scientifique, Observatoire de Paris, Sorbonne Université, Université Paris Saclay, École Polytechnique, Institut Polytechnique de Paris, Paris, France
| | - M. Volwerk
- grid.4299.60000 0001 2169 3852Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - G. Collinson
- grid.133275.10000 0004 0637 6666National Aeronautic and Space Administration, Goddard Space Flight Center, Greenbelt, MD USA
| | - B. Sanchez-Cano
- grid.9918.90000 0004 1936 8411School of Physics and Astronomy, University of Leicester, Leicester, UK
| | - A. Barthe
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - E. Penou
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - S. Yokota
- grid.136593.b0000 0004 0373 3971Department of Earth and Space Science, Graduate School of Science, Osaka University, Osaka, Japan
| | - V. Génot
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - J. A. Sauvaud
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - D. Delcourt
- grid.508893.fLaboratoire de Physique des Plasmas (LPP), Centre National de la Recherche Scientifique, Observatoire de Paris, Sorbonne Université, Université Paris Saclay, École Polytechnique, Institut Polytechnique de Paris, Paris, France
| | - M. Fraenz
- grid.435826.e0000 0001 2284 9011Max-Planck-Institute for Solar System Research, Göttingen, Germany
| | - R. Modolo
- Laboratoire Atmosphères, Milieux, Observations Spatiales, Institut Pierre Simon Laplace, Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Université Pierre Marie Curie, Centre National de la Recherche Scientifique, Guyancourt, France
| | - A. Milillo
- grid.4293.c0000 0004 1792 8585Institute of Space Astrophysics and Planetology, Istituto Nazionale di Astrofisica, Rome, Italy
| | - H.-U. Auster
- grid.6738.a0000 0001 1090 0254Institute for Geophysics and Extraterrestrial Physics, Technische Universität Braunschweig, Braunschweig, Germany
| | - I. Richter
- grid.6738.a0000 0001 1090 0254Institute for Geophysics and Extraterrestrial Physics, Technische Universität Braunschweig, Braunschweig, Germany
| | - J. Z. D. Mieth
- grid.6738.a0000 0001 1090 0254Institute for Geophysics and Extraterrestrial Physics, Technische Universität Braunschweig, Braunschweig, Germany
| | - P. Louarn
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - C. J. Owen
- grid.83440.3b0000000121901201Mullard Space Science Laboratory, University College London, Holmbury St. Mary, UK
| | - T. S. Horbury
- grid.7445.20000 0001 2113 8111Imperial College London, South Kensington Campus, London, UK
| | - K. Asamura
- grid.62167.340000 0001 2220 7916Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Kyoto, Japan
| | - S. Matsuda
- grid.9707.90000 0001 2308 3329Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa, Japan
| | - H. Nilsson
- grid.425140.60000 0001 0706 1867Swedish Institute of Space Physics, Kiruna, Sweden
| | - M. Wieser
- grid.425140.60000 0001 0706 1867Swedish Institute of Space Physics, Kiruna, Sweden
| | - T. Alberti
- grid.4293.c0000 0004 1792 8585Institute of Space Astrophysics and Planetology, Istituto Nazionale di Astrofisica, Rome, Italy
| | - A. Varsani
- grid.4299.60000 0001 2169 3852Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - V. Mangano
- grid.4293.c0000 0004 1792 8585Institute of Space Astrophysics and Planetology, Istituto Nazionale di Astrofisica, Rome, Italy
| | - A. Mura
- grid.4293.c0000 0004 1792 8585Institute of Space Astrophysics and Planetology, Istituto Nazionale di Astrofisica, Rome, Italy
| | - H. Lichtenegger
- grid.4299.60000 0001 2169 3852Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - G. Laky
- grid.4299.60000 0001 2169 3852Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - H. Jeszenszky
- grid.4299.60000 0001 2169 3852Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - K. Masunaga
- grid.62167.340000 0001 2220 7916Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Kyoto, Japan
| | - C. Signoles
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - M. Rojo
- grid.15781.3a0000 0001 0723 035XInstitut de Recherche en Astrophysique et Planétologie, Centre National de la Recherche Scientifique, Centre National d’Etudes Spatiales, Université Paul Sabatier—Toulouse III, Toulouse, France
| | - G. Murakami
- grid.62167.340000 0001 2220 7916Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Kyoto, Japan
| |
Collapse
|
4
|
Orsini S, Milillo A, Lichtenegger H, Varsani A, Barabash S, Livi S, De Angelis E, Alberti T, Laky G, Nilsson H, Phillips M, Aronica A, Kallio E, Wurz P, Olivieri A, Plainaki C, Slavin JA, Dandouras I, Raines JM, Benkhoff J, Zender J, Berthelier JJ, Dosa M, Ho GC, Killen RM, McKenna-Lawlor S, Torkar K, Vaisberg O, Allegrini F, Daglis IA, Dong C, Escoubet CP, Fatemi S, Fränz M, Ivanovski S, Krupp N, Lammer H, Leblanc F, Mangano V, Mura A, Rispoli R, Sarantos M, Smith HT, Wieser M, Camozzi F, Di Lellis AM, Fremuth G, Giner F, Gurnee R, Hayes J, Jeszenszky H, Trantham B, Balaz J, Baumjohann W, Cantatore M, Delcourt D, Delva M, Desai M, Fischer H, Galli A, Grande M, Holmström M, Horvath I, Hsieh KC, Jarvinen R, Johnson RE, Kazakov A, Kecskemety K, Krüger H, Kürbisch C, Leblanc F, Leichtfried M, Mangraviti E, Massetti S, Moissenko D, Moroni M, Noschese R, Nuccilli F, Paschalidis N, Ryno J, Seki K, Shestakov A, Shuvalov S, Sordini R, Stenbeck F, Svensson J, Szalai S, Szego K, Toublanc D, Vertolli N, Wallner R, Vorburger A. Inner southern magnetosphere observation of Mercury via SERENA ion sensors in BepiColombo mission. Nat Commun 2022; 13:7390. [PMID: 36450728 PMCID: PMC9712576 DOI: 10.1038/s41467-022-34988-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Accepted: 11/14/2022] [Indexed: 12/03/2022] Open
Abstract
Mercury's southern inner magnetosphere is an unexplored region as it was not observed by earlier space missions. In October 2021, BepiColombo mission has passed through this region during its first Mercury flyby. Here, we describe the observations of SERENA ion sensors nearby and inside Mercury's magnetosphere. An intermittent high-energy signal, possibly due to an interplanetary magnetic flux rope, has been observed downstream Mercury, together with low energy solar wind. Low energy ions, possibly due to satellite outgassing, were detected outside the magnetosphere. The dayside magnetopause and bow-shock crossing were much closer to the planet than expected, signature of a highly eroded magnetosphere. Different ion populations have been observed inside the magnetosphere, like low latitude boundary layer at magnetopause inbound and partial ring current at dawn close to the planet. These observations are important for understanding the weak magnetosphere behavior so close to the Sun, revealing details never reached before.
Collapse
Affiliation(s)
- S Orsini
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy.
| | - A Milillo
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - H Lichtenegger
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - A Varsani
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - S Barabash
- Swedish Institute of Space Physics, Kiruna, Sweden
| | - S Livi
- Southwest Research Institute, San Antonio, TX, USA
- University of Michigan, Department of Climate and Space Sciences and Engineering, Ann Arbor, MI, USA
| | - E De Angelis
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - T Alberti
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - G Laky
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - H Nilsson
- Swedish Institute of Space Physics, Kiruna, Sweden
| | - M Phillips
- Southwest Research Institute, San Antonio, TX, USA
| | - A Aronica
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - E Kallio
- Aalto University, Department of Electronics and Nanoengineering, School of Electrical Engineering, Helsinki, Finland
| | - P Wurz
- University of Bern, Institute of Physics, Bern, Switzerland
| | | | | | - J A Slavin
- University of Michigan, Department of Climate and Space Sciences and Engineering, Ann Arbor, MI, USA
| | - I Dandouras
- Institut de Recherche en Astrophysique et Planétologie, CNRS, CNES, Université de Toulouse, Toulouse, France
| | - J M Raines
- University of Michigan, Department of Climate and Space Sciences and Engineering, Ann Arbor, MI, USA
| | | | - J Zender
- ESA-ESTEC, Noordwijk, The Netherlands
| | | | - M Dosa
- Wigner Research Centre for Physics, Budapest, Hungary
| | - G C Ho
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, 20723, USA
| | - R M Killen
- NASA/Goddard Space Flight Center, Greenbelt, MD, 20771, USA
| | | | - K Torkar
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - O Vaisberg
- IKI Space Research Institute, Moscow, Russia
| | - F Allegrini
- Southwest Research Institute, San Antonio, TX, USA
- University of Texas at San Antonio, Department of Physics and Astronomy, San Antonio, TX, USA
| | - I A Daglis
- National and Kapodistrian University of Athens, Department of Physics, Athens, Greece
- Hellenic Space Center, Athens, Greece
| | - C Dong
- Princeton Plasma Physics Laboratory and Department of Astrophysical Sciences, Princeton University, Princeton, NJ, USA
| | | | - S Fatemi
- Department of Physics, Umeå University, Umeå, Sweden
| | - M Fränz
- Max-Planck-Institut für Sonnensystemforschung, MPS, 37077, Göttingen, Germany
| | - S Ivanovski
- Astronomincal Observatory, INAF, Trieste, Italy
| | - N Krupp
- Max-Planck-Institut für Sonnensystemforschung, MPS, 37077, Göttingen, Germany
| | - H Lammer
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | | | - V Mangano
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - A Mura
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - R Rispoli
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - M Sarantos
- NASA/Goddard Space Flight Center, Greenbelt, MD, 20771, USA
| | - H T Smith
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, 20723, USA
| | - M Wieser
- Swedish Institute of Space Physics, Kiruna, Sweden
| | | | | | - G Fremuth
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - F Giner
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - R Gurnee
- Laboratory for Atmospheric and Space Physics, Boulder, CO, USA
| | - J Hayes
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD, 20723, USA
| | - H Jeszenszky
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - B Trantham
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - J Balaz
- Institute of Experimental Physics SAS, Slovak Academy of Sciences, 040 01, Košice, Slovakia
| | - W Baumjohann
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | | | | | - M Delva
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - M Desai
- Southwest Research Institute, San Antonio, TX, USA
| | - H Fischer
- Max-Planck-Institut für Sonnensystemforschung, MPS, 37077, Göttingen, Germany
| | - A Galli
- University of Bern, Institute of Physics, Bern, Switzerland
| | - M Grande
- Aberystwyth University, Aberystwyth, Ceredigion, UK
| | - M Holmström
- Swedish Institute of Space Physics, Kiruna, Sweden
| | - I Horvath
- Wigner Research Centre for Physics, Budapest, Hungary
| | - K C Hsieh
- University of Arizona, Tucson, AZ, USA
| | - R Jarvinen
- Aalto University, Department of Electronics and Nanoengineering, School of Electrical Engineering, Helsinki, Finland
- Finnish Meteorological Institute FMI, Helsinki, Finland
| | - R E Johnson
- University of Virginia, Charlottesville, VA, 22904, USA
| | - A Kazakov
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - K Kecskemety
- Wigner Research Centre for Physics, Budapest, Hungary
| | - H Krüger
- Max-Planck-Institut für Sonnensystemforschung, MPS, 37077, Göttingen, Germany
| | - C Kürbisch
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | | | - M Leichtfried
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | | | - S Massetti
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - D Moissenko
- IKI Space Research Institute, Moscow, Russia
| | - M Moroni
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - R Noschese
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - F Nuccilli
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - N Paschalidis
- NASA/Goddard Space Flight Center, Greenbelt, MD, 20771, USA
| | - J Ryno
- Finnish Meteorological Institute FMI, Helsinki, Finland
| | - K Seki
- University of Tokyo, Department of Earth and Planetary Science, Graduate School of Science, Tokyo, Japan
| | - A Shestakov
- IKI Space Research Institute, Moscow, Russia
| | - S Shuvalov
- IKI Space Research Institute, Moscow, Russia
| | - R Sordini
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - F Stenbeck
- Swedish Institute of Space Physics, Kiruna, Sweden
| | - J Svensson
- Swedish Institute of Space Physics, Kiruna, Sweden
| | - S Szalai
- Wigner Research Centre for Physics, Budapest, Hungary
| | - K Szego
- Wigner Research Centre for Physics, Budapest, Hungary
| | - D Toublanc
- Institut de Recherche en Astrophysique et Planétologie, CNRS, CNES, Université de Toulouse, Toulouse, France
| | - N Vertolli
- Institute of Space Astrophysics and Planetology, INAF, Roma, Italy
| | - R Wallner
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - A Vorburger
- University of Bern, Institute of Physics, Bern, Switzerland
| |
Collapse
|
5
|
nunno VD, Franceschi E, Tosoni A, Gatto L, Mura A, Acquaviva G, De Biase D, Bartolini S, Brandes AA. PATH-15. NON-CANONICAL IDH 1 AND IDH 2 MUTATIONS ARE ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH GLIOMAS: RESULTS OF A META-ANALYSIS. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Non-canonical isocitrate dehydrogenase (IDH) mutations are uncommon among patients with grade 2 and 3 gliomas and their clinical significance is still unclear.
METHOD
We carried out a systematic review and meta-analysis to evaluate the prognostic impact of IDH1 and IDH2 non-canonical mutations. We searched English-written articles published on PubMed/Medline, Cochrane library, and Scopus until the 1st May 2021. Keywords adopted for the research were: ‘’IDH’’ OR ‘’IDH1’’ OR ‘’IDH2’’ OR ‘’Isocitrate dehydrogenase’’ AND ‘’glioma’’.
RESULTS
We selected 13 of 3513 studies reporting data of 4007 patients with a diagnosis of grade 2 and grade 3 including 3091 patients with a molecular proven IDH 1 or IDH 2 mutations. Between patients with IDH mutated gliomas, 479 (15.5%) patients showed non-canonical IDH 1 or IDH 2 mutations. The presence of IDH 1 non-canonical mutation occurred in younger age and in non codeleted 1p19q as compared to canonical IDH 1 mutation. However, patients with IDH 2 mutations showed more frequently 1p19q codeletion as compared to those with canonical IDH 1 mutated glioma. Four studies reported complete data survival for patients with non-canonical (n= 160) and canonical mutations (n= 1019). The pooled HR of these studies was 0.47 (95% CI, 0.28-0.81) confirming a positive prognostic role for non-canonical IDH 1 and IDH 2 mutations.
CONCLUSION
The presence of non-canonical IDH 1 and IDH 2 mutations defines a specific subgroup of gliomas occurring at younger age with improved survival. Patients with a non-canonical IDH 1 mutation showed less frequently 1p19q codeletion as compared to those patients harboring a canonical or IDH 2 mutation.
Collapse
Affiliation(s)
| | | | | | | | | | - Giorgia Acquaviva
- Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum-University of Bologna, Bologna, Italy
| | - Dario De Biase
- Department of Pharmacy and Biotechnology (FaBIT) – Molecular Pathology Laboratory, University of Bologna, Bologna, Italy
| | | | | |
Collapse
|
6
|
de Biase D, Acquaviva G, Visani M, Marucci G, De Leo A, Maloberti T, Sanza V, Di Oto E, Franceschi E, Mura A, Ragazzi M, Serra S, Froio E, Bisagni A, Brandes AA, Pession A, Tallini G. Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. J Mol Diagn 2021; 23:1185-1194. [PMID: 34186176 DOI: 10.1016/j.jmoldx.2021.06.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 05/15/2021] [Accepted: 06/08/2021] [Indexed: 02/08/2023] Open
Abstract
The 1p/19q codeletion is the result of a translocation between chromosome 1 (Chr1p) and chromosome 19 (Chr19q) with the loss of derivative (1;19)(p10;q10) chromosome. The 1p/19q codeletion has predictive and prognostic significance, and it is essential for the classification of gliomas. In routine practice, the fluorescence in situ hybridization (FISH) diagnosis of 1p/19q codeletion is sometimes unexpected. This study aimed to develop a next-generation sequencing panel for the concurrent definition of the 1p/19q codeletion and IDH1/IDH2 mutation status to resolve these equivocal cases. A total of 65 glioma samples were investigated using a 1p/19q-single-nucleotide polymorphism (SNP)-IDH panel. The panel consists of 192 amplicons, including SNPs mapping to Chr1 and Chr19 and amplicons for IDH1/IDH2 analysis. The 1p/19q SNP-IDH panel consistently identified IDH1/IDH2 mutations. In 49 of 60 cases (81.7%), it provided the same 1p/19q results obtained by FISH. In the remaining 11 cases, the 1p/19q SNP-IDH panel uncovered partial chromosome imbalances as a result of interstitial amplification or deletion of the regions where the FISH probes map, leading to a mistaken overdiagnosis of 1p/19q codeletion by FISH. The 1p/19q SNP-IDH next-generation sequencing panel allows reliable analysis of the 1p/19q codeletion and IDH1/IDH2 mutation at the same time. The panel not only allows resolution of difficult cases but also represents a cost-effective alternative to standard molecular diagnostics procedures.
Collapse
Affiliation(s)
- Dario de Biase
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy; Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Giorgia Acquaviva
- Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), University of Bologna, Bologna, Italy
| | - Michela Visani
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), University of Bologna, Bologna, Italy
| | - Gianluca Marucci
- Neuropathology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Antonio De Leo
- Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), University of Bologna, Bologna, Italy
| | - Thais Maloberti
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), University of Bologna, Bologna, Italy
| | - Viviana Sanza
- Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), University of Bologna, Bologna, Italy
| | - Enrico Di Oto
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), University of Bologna, Bologna, Italy
| | - Enrico Franceschi
- Department of Oncology, Azienda Unitá Sanitaria Locale (AUSL) Bologna, Bologna, Italy
| | - Antonella Mura
- Department of Oncology, Azienda Unitá Sanitaria Locale (AUSL) Bologna, Bologna, Italy
| | - Moira Ragazzi
- Anatomic Pathology Unit, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Silvia Serra
- Anatomic Pathology Unit, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Elisabetta Froio
- Anatomic Pathology Unit, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Alessandra Bisagni
- Anatomic Pathology Unit, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - Alba A Brandes
- Neuropathology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Annalisa Pession
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy; Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Giovanni Tallini
- Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale), University of Bologna, Bologna, Italy.
| |
Collapse
|
7
|
Di Nunno V, Franceschi E, Tosoni A, Mura A, Minichillo S, Di Battista M, Gatto L, Maggio I, Lodi R, Bartolini S, Brandes AA. Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? Clin Drug Investig 2021; 41:757-773. [PMID: 34403132 DOI: 10.1007/s40261-021-01070-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/25/2021] [Indexed: 11/28/2022]
Abstract
Breast cancer (BC) is the second most common tumour spreading to the central nervous system (CNS). The prognosis of patients with CNS metastases depends on several parameters including the molecular assessment of the disease. Although loco-regional treatment remains the best approach, systemic therapies are acquiring a role leading to remarkable long-lasting responses. The efficacy of these compounds diverges between tumours with different molecular assessments. Promising agents under investigation are drugs targeting the HER2 pathways such as tucatinib, neratinib, pyrotinib, trastuzumab deruxtecan. In addition, there are several promising agents under investigation for patients with triple-negative brain metastases (third-generation taxane, etirinotecan, sacituzumab, immune-checkpoint inhibitors) and hormone receptor-positive brain metastases (CDK 4/5, phosphoinositide-3-kinase-mammalian target of rapamycin [PI3K/mTOR] inhibitors). Also, the systemic treatment of leptomeningeal metastases, which represents a very negative prognostic site of metastases, is likely to change as several compounds are under investigation, some with interesting preliminary results. Here we performed a comprehensive review focusing on the current management of CNS metastases according to molecular subtypes, site of metastases (leptomeningeal vs brain), and systemic treatments under investigation.
Collapse
Affiliation(s)
- Vincenzo Di Nunno
- Department of Oncology, AUSL Bologna, Via Altura 3, 40139, Bologna, Italy.
| | - Enrico Franceschi
- Department of Oncology, AUSL Bologna, Via Altura 3, 40139, Bologna, Italy
| | - Alicia Tosoni
- Department of Oncology, AUSL Bologna, Via Altura 3, 40139, Bologna, Italy
| | - Antonella Mura
- Department of Oncology, AUSL Bologna, Via Altura 3, 40139, Bologna, Italy
| | - Santino Minichillo
- Department of Oncology, AUSL Bologna, Via Altura 3, 40139, Bologna, Italy
| | - Monica Di Battista
- Department of Oncology, AUSL Bologna, Via Altura 3, 40139, Bologna, Italy
| | - Lidia Gatto
- Department of Oncology, AUSL Bologna, Via Altura 3, 40139, Bologna, Italy
| | - Ilaria Maggio
- Department of Oncology, AUSL Bologna, Via Altura 3, 40139, Bologna, Italy
| | - Raffaele Lodi
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
| | - Stefania Bartolini
- Department of Oncology, AUSL Bologna, Via Altura 3, 40139, Bologna, Italy
| | | |
Collapse
|
8
|
Franceschi E, Minichillo S, Tosoni A, Mascarin M, Mura A, Di Battista M, Di Nunno V, Gatto L, Lodi R, Bartolini S, Brandes AA. Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. Tumori 2021; 108:331-337. [PMID: 34002658 DOI: 10.1177/03008916211017213] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE Medulloblastoma is a rare tumor in adults and the use of adjuvant chemotherapy in average risk patients is debated. METHODS Patients included in our study were ⩾16 years of age, had histologically confirmed medulloblastoma, and underwent adjuvant radiotherapy with or without chemotherapy. Average risk was defined according to the Chang classification. RESULTS We included 48 average-risk patients. Median follow-up was 151.5 months (95% confidence interval, 124.5-178.5). Both progression-free survival (PFS) and overall survival (OS) were significantly influenced by adjuvant chemotherapy (PFS: hazard ratio [HR], 0.334, p = 0.05; OS: HR, 0.187, p = 0.017) and by receiving the treatment in a referral center (PFS: HR, 0.250, p = 0.008; OS: HR, 0.295, p = 0.038). CONCLUSIONS Treating patients with average-risk medulloblastoma in a referral center improves both PFS and OS, does adding adjuvant chemotherapy.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Raffaele Lodi
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Emilia-Romagna, Italy
| | | | | |
Collapse
|
9
|
Corradini AG, Cremonini A, Cattani MG, Cucchi MC, Saguatti G, Baldissera A, Mura A, Ciabatti S, Foschini MP. Which type of cancer is detected in breast screening programs? Review of the literature with focus on the most frequent histological features. Pathologica 2021; 113:85-94. [PMID: 34042090 PMCID: PMC8167395 DOI: 10.32074/1591-951x-123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Accepted: 08/12/2020] [Indexed: 12/20/2022] Open
Abstract
Breast cancer is the most frequent type of cancer affecting female patients. The introduction of breast cancer screening programs led to a substantial reduction of mortality from breast cancer. Nevertheless, doubts are being raised on the real efficacy of breast screening programs. The aim of the present paper is to review the main pathological type of cancers detected in breast cancer screening programs. Specifically, attention will be given to: in situ carcinoma, invasive carcinoma histotypes and interval cancer.
Collapse
Affiliation(s)
- Angelo G Corradini
- Unit of Anatomic Pathology, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Anna Cremonini
- Unit of Anatomic Pathology, Department of Oncology, Bellaria Hospital, Bologna, Italy
| | - Maria G Cattani
- Unit of Anatomic Pathology, Department of Oncology, Bellaria Hospital, Bologna, Italy
| | - Maria C Cucchi
- Unit of Breast Surgery, Department of Oncology, Bellaria Hospital, Bologna Italy
| | - Gianni Saguatti
- Unit of Senology, Department of Oncology, Bellaria Hospital, Bologna, Italy
| | | | - Antonella Mura
- Department of Medical Oncology, Azienda USL, Bologna, Italy; IRCCS Institute of Neurological Sciences, Bologna, Italy
| | | | - Maria P Foschini
- Unit of Anatomic Pathology, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.,Unit of Anatomic Pathology, Department of Oncology, Bellaria Hospital, Bologna, Italy
| |
Collapse
|
10
|
Tosoni A, Gatto L, Franceschi E, Di Nunno V, Lodi R, Mura A, Di Battista M, Bartolini S, Brandes AA. Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. Eur J Cancer 2021; 145:171-178. [PMID: 33486440 DOI: 10.1016/j.ejca.2020.12.027] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2020] [Revised: 12/10/2020] [Accepted: 12/20/2020] [Indexed: 12/20/2022]
Abstract
BACKGROUND To date, no prospective study has been conducted to investigate the role of socioeconomic status (SES) on clinical outcome of glioblastoma (GBM) in Italy, where there is a National Health Service that provides universal coverage regardless of the patient's economic status. METHODS We performed a prospective observational study investigating the association between SES and survival in GBM patients at our institution, a hub centre for brain cancer research and treatment. We included GBM patients who underwent medical treatment or chemo-radiation between April 2017 and December 2017. The SES was measured using the income-brackets, attributed by the Italian Ministry of Finance on the basis of the income of the fiscal family unit, referring to the previous year. RESULTS One hundred and six patients were included in the study. In multivariate analysis, overall survival (OS) correlated significantly with higher-income (HR = 0.623.95% CI 0.467-0.832; p = 0.001) and MGMT methylation status (HR = 0.158.95% CI 0.082-0.304; P < 0.001). When adjusted for age, performance status and extension of surgery, survival benefit remained superior for higher-income HR = 0.641 (95% CI 0.478-0.858; p = 0.003) and MGMT methylated tumours HR = 0.167 (95% CI 0.084-0.331; p < 0.001). CONCLUSIONS SES is an important determinant of prognosis in GBM even in the Italian National Health Service, which provides universal, largely free and relatively comprehensive healthcare. Despite aspirations to achieve equality in healthcare, socioeconomic differences exist and may impact the clinical outcome.
Collapse
Affiliation(s)
- Alicia Tosoni
- Department of Medical Oncology, Azienda USL of Bologna, Bologna, Italy
| | - Lidia Gatto
- Department of Medical Oncology, Azienda USL of Bologna, Bologna, Italy
| | - Enrico Franceschi
- Department of Medical Oncology, Azienda USL of Bologna, Bologna, Italy.
| | - Vincenzo Di Nunno
- Department of Medical Oncology, Azienda USL of Bologna, Bologna, Italy
| | - Raffaele Lodi
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology, Azienda USL of Bologna, Bologna, Italy
| | | | | | | |
Collapse
|
11
|
Orsini S, Livi SA, Lichtenegger H, Barabash S, Milillo A, De Angelis E, Phillips M, Laky G, Wieser M, Olivieri A, Plainaki C, Ho G, Killen RM, Slavin JA, Wurz P, Berthelier JJ, Dandouras I, Kallio E, McKenna-Lawlor S, Szalai S, Torkar K, Vaisberg O, Allegrini F, Daglis IA, Dong C, Escoubet CP, Fatemi S, Fränz M, Ivanovski S, Krupp N, Lammer H, Leblanc F, Mangano V, Mura A, Nilsson H, Raines JM, Rispoli R, Sarantos M, Smith HT, Szego K, Aronica A, Camozzi F, Di Lellis AM, Fremuth G, Giner F, Gurnee R, Hayes J, Jeszenszky H, Tominetti F, Trantham B, Balaz J, Baumjohann W, Brienza D, Bührke U, Bush MD, Cantatore M, Cibella S, Colasanti L, Cremonese G, Cremonesi L, D'Alessandro M, Delcourt D, Delva M, Desai M, Fama M, Ferris M, Fischer H, Gaggero A, Gamborino D, Garnier P, Gibson WC, Goldstein R, Grande M, Grishin V, Haggerty D, Holmström M, Horvath I, Hsieh KC, Jacques A, Johnson RE, Kazakov A, Kecskemety K, Krüger H, Kürbisch C, Lazzarotto F, Leblanc F, Leichtfried M, Leoni R, Loose A, Maschietti D, Massetti S, Mattioli F, Miller G, Moissenko D, Morbidini A, Noschese R, Nuccilli F, Nunez C, Paschalidis N, Persyn S, Piazza D, Oja M, Ryno J, Schmidt W, Scheer JA, Shestakov A, Shuvalov S, Seki K, Selci S, Smith K, Sordini R, Svensson J, Szalai L, Toublanc D, Urdiales C, Varsani A, Vertolli N, Wallner R, Wahlstroem P, Wilson P, Zampieri S. SERENA: Particle Instrument Suite for Determining the Sun-Mercury Interaction from BepiColombo. Space Sci Rev 2021; 217:11. [PMID: 33487762 PMCID: PMC7803725 DOI: 10.1007/s11214-020-00787-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Accepted: 12/03/2020] [Indexed: 06/12/2023]
Abstract
The ESA-JAXA BepiColombo mission to Mercury will provide simultaneous measurements from two spacecraft, offering an unprecedented opportunity to investigate magnetospheric and exospheric particle dynamics at Mercury as well as their interactions with solar wind, solar radiation, and interplanetary dust. The particle instrument suite SERENA (Search for Exospheric Refilling and Emitted Natural Abundances) is flying in space on-board the BepiColombo Mercury Planetary Orbiter (MPO) and is the only instrument for ion and neutral particle detection aboard the MPO. It comprises four independent sensors: ELENA for neutral particle flow detection, Strofio for neutral gas detection, PICAM for planetary ions observations, and MIPA, mostly for solar wind ion measurements. SERENA is managed by a System Control Unit located inside the ELENA box. In the present paper the scientific goals of this suite are described, and then the four units are detailed, as well as their major features and calibration results. Finally, the SERENA operational activities are shown during the orbital path around Mercury, with also some reference to the activities planned during the long cruise phase.
Collapse
Affiliation(s)
- S Orsini
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - S A Livi
- Southwest Research Institute, San Antonio, TX USA
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, MI USA
| | - H Lichtenegger
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - S Barabash
- Swedish Institute of Space Physics, Kiruna, Sweden
| | - A Milillo
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - E De Angelis
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - M Phillips
- Southwest Research Institute, San Antonio, TX USA
| | - G Laky
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - M Wieser
- Swedish Institute of Space Physics, Kiruna, Sweden
| | | | | | - G Ho
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723 USA
| | - R M Killen
- NASA/Goddard Space Flight Center, Greenbelt, MD 20771 USA
| | - J A Slavin
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, MI USA
| | - P Wurz
- Physics Institute, University of Bern, Bern, Switzerland
| | | | - I Dandouras
- Institut de Recherche en Astrophysique et Planétologie, CNRS, CNES, Université de Toulouse, Toulouse, France
| | - E Kallio
- School of Electrical Engineering, Department of Electronics and Nanoengineering, Aalto University, Helsinki, Finland
| | | | - S Szalai
- Wigner Research Centre for Physics, Budapest, Hungary
| | - K Torkar
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - O Vaisberg
- IKI Space Research Institute, Moscow, Russia
| | - F Allegrini
- Southwest Research Institute, San Antonio, TX USA
| | - I A Daglis
- Department of Physics, National and Kapodistrian University of Athens, Athens, Greece
- Hellenic Space Center, Athens, Greece
| | - C Dong
- Department of Astrophysical Sciences and Princeton Plasma Physics Laboratory, Princeton University, Princeton, NJ USA
| | | | - S Fatemi
- Swedish Institute of Space Physics, Kiruna, Sweden
| | - M Fränz
- Max-Planck-Institut für Sonnensystemforschung, MPS, 37077 Göttingen, Germany
| | - S Ivanovski
- Astronomical Observatory, INAF, Trieste, Italy
| | - N Krupp
- Max-Planck-Institut für Sonnensystemforschung, MPS, 37077 Göttingen, Germany
| | - H Lammer
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | | | - V Mangano
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - A Mura
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - H Nilsson
- Swedish Institute of Space Physics, Kiruna, Sweden
| | - J M Raines
- Department of Climate and Space Sciences and Engineering, University of Michigan, Ann Arbor, MI USA
| | - R Rispoli
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - M Sarantos
- NASA/Goddard Space Flight Center, Greenbelt, MD 20771 USA
| | - H T Smith
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723 USA
| | - K Szego
- Wigner Research Centre for Physics, Budapest, Hungary
| | - A Aronica
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | | | | | - G Fremuth
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - F Giner
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - R Gurnee
- Laboratory for Atmospheric and Space Physics, Boulder, CO USA
| | - J Hayes
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723 USA
| | - H Jeszenszky
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | | | - B Trantham
- Southwest Research Institute, San Antonio, TX USA
| | - J Balaz
- Institute of Experimental Physics SAS, Slovak Academy of Sciences, 040 01 Košice, Slovakia
| | - W Baumjohann
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - D Brienza
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - U Bührke
- Max-Planck-Institut für Sonnensystemforschung, MPS, 37077 Göttingen, Germany
| | - M D Bush
- Physics Institute, University of Bern, Bern, Switzerland
| | | | - S Cibella
- Istituto di Struttura della Materia (CNR-ISM), 00133 Roma, Italy
| | - L Colasanti
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - G Cremonese
- Astronomical Observatory, INAF, Padova, Italy
| | | | - M D'Alessandro
- Istituto di Struttura della Materia (CNR-ISM), 00133 Roma, Italy
| | | | - M Delva
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - M Desai
- Southwest Research Institute, San Antonio, TX USA
| | - M Fama
- Comisión Nacional de Energía Atómica, cnea, Centro Atómico Bariloche, Bariloche, Argentina
| | - M Ferris
- Southwest Research Institute, San Antonio, TX USA
| | - H Fischer
- Max-Planck-Institut für Sonnensystemforschung, MPS, 37077 Göttingen, Germany
| | - A Gaggero
- Istituto di Struttura della Materia (CNR-ISM), 00133 Roma, Italy
| | - D Gamborino
- Physics Institute, University of Bern, Bern, Switzerland
| | - P Garnier
- Institut de Recherche en Astrophysique et Planétologie, CNRS, CNES, Université de Toulouse, Toulouse, France
| | - W C Gibson
- Southwest Research Institute, San Antonio, TX USA
| | - R Goldstein
- Southwest Research Institute, San Antonio, TX USA
| | - M Grande
- Aberystwyth University, Aberystwyth, Ceredigion SY23 3FL UK
| | - V Grishin
- IKI Space Research Institute, Moscow, Russia
| | - D Haggerty
- The Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723 USA
| | - M Holmström
- Swedish Institute of Space Physics, Kiruna, Sweden
| | - I Horvath
- Wigner Research Centre for Physics, Budapest, Hungary
| | - K-C Hsieh
- University of Arizona, Tucson, AZ USA
| | - A Jacques
- NASA/Goddard Space Flight Center, Greenbelt, MD 20771 USA
| | - R E Johnson
- University of Virginia, Charlottesville, VA 22904 USA
| | - A Kazakov
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - K Kecskemety
- Wigner Research Centre for Physics, Budapest, Hungary
| | - H Krüger
- Max-Planck-Institut für Sonnensystemforschung, MPS, 37077 Göttingen, Germany
| | - C Kürbisch
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | | | | | - M Leichtfried
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | | | - A Loose
- Max-Planck-Institut für Sonnensystemforschung, MPS, 37077 Göttingen, Germany
| | - D Maschietti
- Istituto Fotonica e Nanotecnologie, CNR-IFN, Roma, Italy
| | - S Massetti
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | | | - G Miller
- Southwest Research Institute, San Antonio, TX USA
| | - D Moissenko
- IKI Space Research Institute, Moscow, Russia
| | - A Morbidini
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - R Noschese
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - F Nuccilli
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - C Nunez
- Southwest Research Institute, San Antonio, TX USA
| | - N Paschalidis
- NASA/Goddard Space Flight Center, Greenbelt, MD 20771 USA
| | - S Persyn
- Southwest Research Institute, San Antonio, TX USA
| | - D Piazza
- Physics Institute, University of Bern, Bern, Switzerland
| | - M Oja
- Swedish Institute of Space Physics, Kiruna, Sweden
| | - J Ryno
- Finnish Meteorological Institute FMI, Helsinki, Finland
| | - W Schmidt
- Finnish Meteorological Institute FMI, Helsinki, Finland
| | | | - A Shestakov
- IKI Space Research Institute, Moscow, Russia
| | - S Shuvalov
- IKI Space Research Institute, Moscow, Russia
| | - K Seki
- Department of Earth and Planetary Science, Graduate School of Science, University of Tokyo, Tokyo, Japan
| | - S Selci
- Istituto di Struttura della Materia (CNR-ISM), 00133 Roma, Italy
| | - K Smith
- Southwest Research Institute, San Antonio, TX USA
| | - R Sordini
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | | | - L Szalai
- Wigner Research Centre for Physics, Budapest, Hungary
| | - D Toublanc
- Institut de Recherche en Astrophysique et Planétologie, CNRS, CNES, Université de Toulouse, Toulouse, France
| | - C Urdiales
- Southwest Research Institute, San Antonio, TX USA
| | - A Varsani
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - N Vertolli
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| | - R Wallner
- Space Research Institute, Austrian Academy of Sciences, Graz, Austria
| | - P Wahlstroem
- Physics Institute, University of Bern, Bern, Switzerland
| | - P Wilson
- Southwest Research Institute, San Antonio, TX USA
| | - S Zampieri
- Institute of Space Astrophysics and Planetology, INAF, via del Fosso del Cavaliere 100, 00133 Rome, Italy
| |
Collapse
|
12
|
Harrison SL, Lane DA, Banach M, Mastej M, Kasperczyk S, Jóźwiak JJ, Lip GY, Al-Shaer B, Andrusewicz W, Andrzejczuk-Rosa M, Anusz-Gaszewska E, Bagińska A, Balawajder P, Bańka G, Barańska-Skubisz E, Barbara Przyczyna B, Bartkowiak S, Bartodziej J, Bartosiewicz M, Basałyga M, Batyra A, Bąk A, Bednarz M, Bejnar K, Bernacki W, Betiuk-Kwiatkowska M, Biegaj S, Bień M, Bilski W, Biłogan M, Biruta-Pawłowska G, Biskup A, Błaszczyk B, Błaszczyk H, Błońska-Jankowska T, Bogacka-Gancarczyk B, Bojanowska M, Bonda E, Borowik-Skwarek J, Borowska J, Bruckner J, Brzostek J, Brzuchacz M, Budzyńska M, Bulzacka-Fugiel I, Bulzak J, Bunikowski K, Cebulska A, Celka T, Cempel-Nowak E, Chechliński W, Chludzińska A, Chmiel D, Chmielewska M, Cichy M, Ciemięga A, Ciepluch A, Cieszyńska I, Czajka B, Czapla B, Czerner M, Czerwińska B, Czuryszkiewicz W, Daleka E, Dawid Z, Dąbrowska M, Dąbrowska R, Dąbrowski D, Dąbrowski M, Demczyszyn K, Dębowska-Serwińska A, Dmochowski J, Dobrzecka-Kiwior J, Dolanowska E, Dolanowski H, Dołek P, Domagała M, Domański H, Doszel A, Duda D, Dudkowska M, Dudziuk B, Dybciak P, Dymanowski M, Dziadzio-Bolek L, Eicke M, El-Hassan H, Eremus A, Fąferek-Muller M, Figura-Roguska E, Fijałkowska-Kaczmarek I, Flis M, Florczak T, Florczuk M, Foryszewska-Witan E, Frydrych W, Fugiel A, Futyma E, Gaca-Jaroszewicz A, Gajdamowicz I, Ganczarski K, Gatnar A, Gers M, Głowacki A, Głód K, Godula J, Gołąb J, Gołębiewski M, Goszczyńska E, Gościcka K, Górna-Hajduga A, Górny E, Grabowska T, Grabowski R, Graczyk-Duda A, Gromow A, Grudewicz A, Gruszecka J, Gruszka A, Gryboś J, Grzebyk J, Grzechowiak A, Grzesiak D, Grześkowiak T, Guźla A, Hachuła G, Hawel B, Hiltawska H, Honkowicz E, Ignatowicz J, Imielski K, Iwaniura A, Jagieła-Szymala A, Jalć-Sowała M, Janczylik A, Janisz E, Janiszek M, Jankiewicz-Ziobro K, Januszewska K, Jaremek A, Jaros-Urbaniak A, Jarosz J, Jarosz P, Jasiński W, Jezierska-Wasilewska M, Jędraszewski T, Jędrzejowska A, Józefowicz R, Jóźwiak J, Juźwin K, Kacprzak E, Kaczmarek-Szewczyk J, Kaczmarzyk M, Kandziora R, Kaniewski C, Karolak-Brandt L, Kasperczyk S, Kasperek-Dyląg E, Kedziora I, Kępa A, Kiciński J, Kielak-Al-Hosam J, Kiełczawa Ł, Kilimowicz P, Kitliński K, Kiwka T, Klein U, Klichowicz L, Klimowicz A, Klonowski B, Kmolek B, Kobyłko-Klepacka E, Kocoń A, Kolenda A, Kollek E, Kopeć M, Koper-Kozikowska B, Koralewska J, Korczyńska M, Korzeniewski M, Kosk A, Kotarski K, Kowalczyk E, Kowalczyk M, Kowalik I, Kozak-Błażkiewicz B, Kozik M, Kozłowska D, Kozłowska E, Kozłowska M, Kozubski T, Kózka K, Kraśnik L, Krężel T, Krochmal B, Król B, Król G, Król J, Królikowska T, Kruszewska H, Krygier-Potrykus B, Krystek W, Krzysztoń J, Kubicki T, Kuczmierczyk-El-Hassan A, Kuczyńska-Witek W, Kujda D, Kurowski A, Kurzelewska-Solarz I, Kwaczyńska M, Kwaśniak M, Kwaśniak P, Kwietniewska T, Łebek-Ordon A, Lebiedowicz A, Lejkowska-Olszewska L, Lentas M, Lesiewicz-Ksycińska A, Limanowski M, Łoniewski S, Łopata J, Łubianka B, Łukasiuk I, Łużna M, Łysiak M, Łysik B, Machowski Z, Maciaczyk-Kubiak J, Mackiewicz-Zabochnicka G, Magner-Krężel Z, Majda S, Malinowski P, Mantyka J, Marchlik E, Martyna-Ordyniec G, Marzec J, Marzec M, Matejko-Wałkiewicz R, Mazur M, Michalczak M, Michalska-Żyłka A, Michniewicz M, Mika-Staniszewska D, Mikiciuk E, Mikołajczak T, Milewski J, Miller E, Misiaszek B, Mizik-Łukowska M, Młyńczyk-Pokutycka E, Mocek M, Moczała M, Morawska-Hermanowicz M, Moryc P, Moskal A, Moskal S, Moździerz A, Moździerz P, Mrozińska M, Mrozowicz K, Mróz G, Munia T, Mura A, Muras-Skudlarska M, Murawska E, Murawski Ł, Murawski R, Musielak R, Nadaj K, Nagarnowicz W, Napierała R, Niedźwiecka M, Niemirski A, Nikiel J, Nosal M, Nowacki W, Nowak J, Nyrka M, Obst A, Ochowicz J, Ogonowska E, Oleszczyk M, Ołdakowski A, Ołowniuk-Stefaniak I, Ordowska-Rejman J, Orliński M, Osińska B, Ostańska-Burian A, Paciorkowska A, Paczkowska U, Paluch L, Pałka L, Paszko-Wojtkowska J, Paszkowska A, Pawlak-Ganczarska E, Pawlik W, Pawłowska I, Paździora M, Permiakow G, Petlic-Marendziak A, Piasecka T, Piaścińska E, Piktel A, Pilarska-Igielska A, Piotrkowska A, Piwowar-Klag K, Planer M, Plewa J, Płatkiewicz P, Płonczyńska B, Podgórska A, Polewska M, Porębska B, Porwoł P, Potakowska I, Prokop A, Przybylski J, Przybyła M, Psiuk H, Ptak K, Puzoń G, Rabiza N, Rachwalik S, Raczyńska E, Raniszewska M, Romanek-Kozik A, Rosa A, Rosa K, Rozewicz A, Rudzka-Kałwak J, Rusak J, Rutkowska D, Rybacki M, Rybińska D, Rycyk-Sadowska A, Rynda L, Rynkiewicz B, Sadowska-Krawczyk B, Sadowska-Zarzycka M, Sarnecka B, Sawalach-Tomanik E, Sidor-Drozd B, Siemieniak-Dębska M, Sieroń A, Siewniak-Zalewska B, Sikora A, Sitarska-Pawlina B, Skorupski J, Skrzypińska-Mansfeld I, Skubisz J, Skwarek R, Słodyczka M, Smentek M, Smolińska K, Solarz B, Sosnowska W, Sroka B, Stachura H, Stangreciak D, Staniak M, Stańczyk Z, Stańszczak-Ozga D, Startek E, Stefańczyk M, Stelmach R, Sternadel-Rączka E, Sternik M, Stępień J, Stocka J, Stokowska-Wojda M, Studler-Karpińska M, Suchorukow W, Sufryd W, Supłacz B, Sygacz J, Szczepański Ł, Szkandera J, Szłapa-Zellner J, Szydlarska D, Śliwa T, Śliwka J, Śmiejkowski Ł, Targońska A, Tesarska E, Tobiasz M, Tomaka J, Tomalska-Bywalec K, Tomiak E, Topczewski S, Trawińska A, Trela-Mucha L, Trojanowski D, Trzaskowska M, Trzcińska-Larska B, Trznadel-Mozul A, Ulanicka-Liwoch K, Urbanowicz M, Uthke-Kluzek A, Waczyński J, Walczak J, Warsz L, Wasyńczuk M, Wąchała-Jędras U, Wąsowicz D, Wczysła J, Wenda F, Werner-Kubicka E, Weryszko E, Węgrzynowska B, Wiaksa M, Wiankowski M, Wicherek A, Wieczorek R, Wiencek R, Wienzek-Tatara G, Wierzbicka B, Wierzbicki M, Wilczyńska B, Wilmańska D, Winiarski P, Wiszniewska-Pabiszczak A, Witkowska M, Witzling J, Wlaź A, Wojtkowiak I, Woydyłło J, Woźniak K, Wójtowicz A, Wrona J, Wrońska M, Wujkowska H, Wyrąbek J, Wysokiński O, Zakrzewski R, Zaleska-Zatkalik J, Zaleski J, Zalewska- Dybciak M, Zalewska E, Zalewska-Uchimiak B, Zawadzka-Krajewska J, Zawadzki J, Zieliński A, Zubrycka E, Żybort I, Żymełka M. Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGRAM2015 study. Atherosclerosis 2020; 312:16-22. [DOI: 10.1016/j.atherosclerosis.2020.08.026] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Revised: 08/04/2020] [Accepted: 08/13/2020] [Indexed: 12/22/2022]
|
13
|
Di Nunno V, Franceschi E, Tosoni A, Di Battista M, Gatto L, Lamperini C, Minichillo S, Mura A, Bartolini S, Brandes AA. Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert Rev Anticancer Ther 2020; 20:785-795. [PMID: 32799576 DOI: 10.1080/14737140.2020.1807949] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Almost all patients affected by glioblastoma experience recurrence of the disease. AREAS COVERED Management of recurrent glioblastoma is a clinical challenge, and several elements should be taken into consideration when making treatment choice. Loco-regional treatments may be the best treatment approach in selected cases while systemic therapies or supportive care alone are necessary for other patients. Unfortunately, few drugs have shown clinical in this setting. This lack of effective treatments has made recurrent glioblastoma a disease orphan of an effective approach. EXPERT OPINION Results of recent clinical trials offer interesting perspectives and may controvert this axiom.
Collapse
Affiliation(s)
- Vincenzo Di Nunno
- Department of Medical Oncology - Azienda USL di Bologna , Bologna, Italy
| | - Enrico Franceschi
- Department of Medical Oncology - Azienda USL di Bologna , Bologna, Italy
| | - Alicia Tosoni
- Department of Medical Oncology - Azienda USL di Bologna , Bologna, Italy
| | - Monica Di Battista
- Department of Medical Oncology - Azienda USL di Bologna , Bologna, Italy
| | - Lidia Gatto
- Department of Medical Oncology - Azienda USL di Bologna , Bologna, Italy
| | - Cinzia Lamperini
- Department of Medical Oncology - Azienda USL di Bologna , Bologna, Italy
| | - Santino Minichillo
- Department of Medical Oncology - Azienda USL di Bologna , Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology - Azienda USL di Bologna , Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology - Azienda USL di Bologna , Bologna, Italy
| | - Alba A Brandes
- Department of Medical Oncology - Azienda USL di Bologna , Bologna, Italy
| |
Collapse
|
14
|
Gatto L, Tosoni A, Franceschi E, Di Nunno V, Minichillo S, Mura A, Di Battista M, Lamperini C, Mosca M, Nuvola G, Sisi M, Bartolini S, Brandes A. 367MO Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective, observational study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
15
|
Franceschi E, Di Nunno V, Tosoni A, Gatto L, Di Battista M, Minichillo S, Mura A, Lamperini C, Nuvola G, Sisi M, Mosca M, Bartolini S, Brandes A. 378P MGMT status influences prognosis of patients with IDH wild type grade III gliomas. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
16
|
Franceschi E, Minichillo S, Mura A, Tosoni A, Mascarin M, Tomasello C, Bartolini S, Brandes AA. Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study. BMC Cancer 2020; 20:755. [PMID: 32787805 PMCID: PMC7425050 DOI: 10.1186/s12885-020-07237-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Accepted: 07/29/2020] [Indexed: 12/28/2022] Open
Abstract
Background Medulloblastoma is extremely rare in adults. The role of chemotherapy for average-risk adult patients remains controversial. Surgery and radiotherapy provide a significant disease control and a good prognosis, but about 25% of average-risk patients have a relapse and die because of disease progression. No data in average-risk adult patients are available to compareradiotherapy alone and radiotherapyfollowed byadjuvant chemotherapy. Methods We analyzed 48 average-risk patients according to Chang classification diagnosed from 1988 to 2016. Results Median age was 29 years (range 16–61). Based on histological subtypes, 15 patients (31.3%) had classic, 15 patients (31.3%) had desmoplastic, 5 patients (10.4%) had extensive nodularity and 2 patients (4.2%) had large cells/anaplastic medulloblastoma. Twenty-four patients (50%) received adjuvant radiotherapy alone and 24 (50%) received radiotherapy and chemotherapy. After a median follow-up of 12.5 years, we found that chemotherapyincreases progression-free survival (PFS-15 82.3 ± 8.0% in patients treated with radiotherapy and chemotherapyvs. 38.5% ± 13.0% in patients treated with radiotherapy alone p = 0.05) and overall survival (OS-15 89.3% ± 7.2% vs. 52.0% ± 13.1%, p = 0.02). Among patients receiving chemotherapy, the reported grade ≥ 3 adverse events were: 9 cases of neutropenia (6 cases of G3 neutropenia [25%] and 3 cases of G4 neutropenia [13%]), 1 case of G3 thrombocytopenia (4%) and 2 cases of G3 nausea (8%). Conclusions Our study with a long follow up period suggests that adding adjuvant chemotherapy to radiotherapy might improve PFS and OS in average-risk adult medulloblastoma patients.
Collapse
Affiliation(s)
- E Franceschi
- Department of Medical Oncology, Azienda USL, Bologna, Italy.
| | - S Minichillo
- Department of Medical Oncology, Azienda USL, Bologna, Italy
| | - A Mura
- Department of Medical Oncology, Azienda USL, Bologna, Italy
| | - A Tosoni
- Department of Medical Oncology, Azienda USL, Bologna, Italy
| | - M Mascarin
- SOSD Oncologia Integrata del Giovane e Radioterapia Pediatrica, Centro di Riferimento Oncologico (CRO) IRCCS, Aviano, Italy
| | - C Tomasello
- Department of Medical Oncology, Papardo Hospital, Messina, Italy
| | - S Bartolini
- Department of Medical Oncology, Azienda USL, Bologna, Italy
| | - A A Brandes
- Department of Medical Oncology, Azienda USL, Bologna, Italy
| |
Collapse
|
17
|
Franceschi E, Tosoni A, Bartolini S, Minichillo S, Mura A, Asioli S, Bartolini D, Gardiman M, Gessi M, Ghimenton C, Giangaspero F, Lanza G, Marucci G, Novello M, Silini EM, Zunarelli E, Paccapelo A, Brandes AA. Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. Eur J Cancer 2020; 137:10-17. [PMID: 32721633 DOI: 10.1016/j.ejca.2020.06.018] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Revised: 05/03/2020] [Accepted: 06/10/2020] [Indexed: 12/26/2022]
Abstract
BACKGROUND Diffuse grade II and grade III gliomas are actually classified in accordance with the presence of isocitrate dehydrogenase mutation (IDH-mut) and the deletion of both 1p and 19q chromosome arms (1p/19q codel). The role of tumour grading as independent prognostic factor in these group of tumours remains matter of debate. The aim of this study was to determine if grade is an independent prognostic factor and not somehow associated to IDH mutation and 1p/19q status of the tumour. METHODS We analysed 399 consecutive patients with newly diagnosed, histologically proven World Health Organisation (WHO) 2016 grade II or grade III IDH-mut gliomas, assessed by polymerase chain reaction, immunohistochemistry or next-generation sequencing (NGS). RESULTS The analysis included 399 patients with grade II (n = 250, 62.7%) or grade III (n = 149, 37.3%) diffuse gliomas. Median follow-up time was 105.3 months. Median survival was 148.1 months. In multivariate analysis, grade II (hazard ratio [HR] = 0.342, 95% confidence interval [CI]: 0.221-0.531; P < 0.001) and 1p/19q codeletion (HR = 0.440, 95% CI: 0.290-0.668; P < 0.001) were independently associated with a lower risk for death. The difference in survival remained significant (p = 0.006 in astrocytomas, p = 0.014 in oligodendrogliomas) when adjusted for histological subtype. Residual disease after surgery (or biopsy) negatively affected survival (HR: 2.151, 95% CI: 1.375-3.367, P = 0.001). Post-surgical treatment with radiotherapy + adjuvant chemotherapy improved survival compared with follow-up and other treatments (HR: 0.316, 95% CI: 0.156-0.641, P = 0.001). CONCLUSIONS In our study, histopathological grade still affects survival in IDH-mutant WHO grade II and III diffuse gliomas. This effect appears to be independent from molecular features, extension of surgical resection and post-surgical treatments. Therefore, physicians should continue to take into account tumour grade, along their molecular characteristics, for a better clinical and therapeutic management of the patients.
Collapse
Affiliation(s)
- Enrico Franceschi
- Department of Medical Oncology, AUSL / IRCCS Institute of Neurological Sciences, Bologna, Italy.
| | - Alicia Tosoni
- Department of Medical Oncology, AUSL / IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology, AUSL / IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Santino Minichillo
- Department of Medical Oncology, AUSL / IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology, AUSL / IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Sofia Asioli
- Section of Anatomic Pathology 'M. Malpighi', Bellaria Hospital, Bologna, Italy; Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | | | | | - Marco Gessi
- Division of Histopathology, Fondazione Policlinico Universitario "A.Gemelli,", Università Cattolica S.Cuore, Roma, Italy
| | - Claudio Ghimenton
- Department of Pathology, Azienda Ospedaliera Universitaria Integrata Verona, Ospedale Civile Maggiore, Borgo Trento, Verona, Italy
| | - Felice Giangaspero
- Department of Radiological, Oncological and Anatomo-pathological Sciences, Sapienza University of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy
| | - Giovanni Lanza
- Department of Pathology, S Anna University Hospital & University of Ferrara, Ferrara, Italy
| | - Gianluca Marucci
- Neuropathology Unit, Fondazione IRCCS, Istituto Neurologico C. Besta, Milan, Italy
| | | | | | | | - Alexandro Paccapelo
- Department of Medical Oncology, AUSL / IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alba A Brandes
- Department of Medical Oncology, AUSL / IRCCS Institute of Neurological Sciences, Bologna, Italy
| |
Collapse
|
18
|
Franceschi E, Tosoni A, Di Nunno V, Mura A, Asioli S, Pession A, Agati R, Paccapelo A, Bartolini S, Brandes AA. MGMT methylation as a prognostic factor in IDH wild type anaplastic gliomas. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.2523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2523 Background: Anaplastic gliomas are classified according to the presence of IDH-mutation. IDH wild type (IDH wt) is associated with poor prognosis and limited effectiveness of treatments.The aim of this study was to find out if MGMT methylation represents a prognostic factor in this setting. Methods: Anaplastic gliomas are classified according to the presence of IDH-mutation. IDH wild type (IDH wt) is associated with poor prognosis and limited effectiveness of treatments.The aim of this study was to find out if MGMT methylation represents a prognostic factor in this setting. Results: The analysis included 73 pts with grade III, IDH wt (19.3%) gliomas. Median follow-up time was 69.9 months. Median age was 50 (Range: 18-75), M/F ratio was 40(54.8%)/33(45.2%).MGMT promoter was methylated in 34 pts (46.6%) and unmethylated in 39 pts (53.4%). After surgery, 9 pts (12.3%) received RT alone, 57 pts (78.1%) received both RT and CT (sequential, concomitant or both). Median survival was 26.2 months. In multivariate analysis age (HR = 1.064, 95%CI: 1.030-1.099; P < 0.001) and MGMT methylation (HR = 0.422, 95%CI: 0.210-0.848; P = 0.015) were independently associated with risk for death. Conclusions: IDH wild type confers a dismal prognosis in patients with grade III gliomas. MGMT methylation, as was demonstrated in glioblastoma, represents a prognostic factor that correlated with lower risk for death. Further studies will investigate potential correlations with treatments.
Collapse
Affiliation(s)
- Enrico Franceschi
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alicia Tosoni
- Medical Oncology Department, Bellaria-Maggiore Hospital, Azienda USL of Bologna-IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Vincenzo Di Nunno
- Department of Medical Oncology, Bellaria Hospital / IRCCS Institute of Neurological Sciences, Bologna, Italy, Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology, Azienda USL / IRCCS Institute of Neurological Sciences, Bologna, Italy, Bologna, Italy
| | - Sofia Asioli
- Department of Biomedical and Neuromotor Sciences (DIBINEM)-Surgical Pathology Section- Alma Mater Studiorum - University of Bologna, Universita degli Studi di Bologna Scuola di Medicina e Chirurgia, Bologna, Italy
| | - Annalisa Pession
- Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Raffaele Agati
- Neuroradiology Department, IRCCS of Neurological Sciences, Bellaria Hospital, Bologna, Italy
| | - Alexandro Paccapelo
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology, Azienda USL– IRCCS Institute of Neurological Science, Bologna, Italy
| | | |
Collapse
|
19
|
Dinelli BM, Adriani A, Mura A, Altieri F, Migliorini A, Moriconi ML. JUNO/JIRAM's view of Jupiter's H 3+ emissions. Philos Trans A Math Phys Eng Sci 2019; 377:20180406. [PMID: 31378178 PMCID: PMC6710896 DOI: 10.1098/rsta.2018.0406] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 03/29/2019] [Indexed: 05/20/2023]
Abstract
The instrument JIRAM (Jovian Infrared Auroral Mapper), on board the NASA spacecraft Juno, is both an imager and a spectrometer. Two distinct detectors are used for imaging and spectroscopy. The imager acquires Jupiter images in two bands, one of which (L band, 3.3-3.6 μm) is devoted to monitor the H3+ emission. The spectrometer covers the spectral region from 2 to 5 μm (average spectral resolution 9 nm) with a 256 pixels slit that can observe the same scene of the L band imager with some delay. JIRAM scientific goals are the exploration of the Jovian aurorae and the planet's atmospheric structure, dynamics and composition. Starting early July 2016 Juno is orbiting around Jupiter. Since then, JIRAM has provided an unprecedented amount of measurements, monitoring both Jupiter's atmosphere and aurorae. In particular, the camera has monitored Jupiter's poles with very high spatial resolution, providing new insights in both its aurorae and the polar dynamic. The main findings obtained by the L imager are detailed pictures of Jupiter's aurorae showing an extremely complex morphology of the H3+ distribution in the main oval and in the moon's footprints. The spectrometer has enabled the measure the distribution of both H3+ concentration and temperature. The analysis of the north auroral region limb observations shows that the peak density of H3+ is above 750 km and that often it is anticorrelated to the temperature, confirming the infrared cooling effect of H3+. This article is part of a discussion meeting issue 'Advances in hydrogen molecular ions: H3+, H5+ and beyond'.
Collapse
Affiliation(s)
| | - A. Adriani
- IAPS-INAF, Via Fosso del Cavaliere 100, Roma, Italy
| | - A. Mura
- IAPS-INAF, Via Fosso del Cavaliere 100, Roma, Italy
| | - F. Altieri
- IAPS-INAF, Via Fosso del Cavaliere 100, Roma, Italy
| | | | | |
Collapse
|
20
|
Franceschi E, Mura A, Lamberti G, De Biase D, Tosoni A, Di Battista M, Argento C, Visani M, Paccapelo A, Bartolini S, Brandes AA. Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas. Future Oncol 2019; 15:2595-2601. [PMID: 31339049 DOI: 10.2217/fon-2019-0093] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Aim: European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria are used to choose treatment in low-grade gliomas. However, no data exist on their concordance. Methods: Low-grade glioma patients treated at our institution from 1998 to 2015 and assessable for both RTOG and EORTC criteria were included to analyze their concordance. Surgery extension, postsurgical treatments, molecular characteristics (IDH mutation, MGMT methylation and 1p/19q codeletion) were recorded. Results: We included 99 patients. The concordance was low (50.5%; K = 0.127; p = 0.021) but for two subgroups: EORTC high-risk patients were also RTOG high-risk patients (concordance: 97.5%) and RTOG low-risk patients were also EORTC low-risk patients (concordance: 90.9%). Conclusion: The concordance between RTOG and EORTC criteria is low. Thus, clinical trials adopting different risk criteria are not comparable.
Collapse
Affiliation(s)
- Enrico Franceschi
- Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Giuseppe Lamberti
- Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Dario De Biase
- Department of Pharmacy & Biotechnology - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Alicia Tosoni
- Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Monica Di Battista
- Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Chiara Argento
- Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Michela Visani
- Department of Experimental, Diagnostic & Specialty Medicine - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Alexandro Paccapelo
- Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alba Ariela Brandes
- Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy
| |
Collapse
|
21
|
Lamberti G, Franceschi E, Tosoni A, Mura A, Paccapelo A, Foschini MP, Asioli S, De Biase D, Pession A, Tallini G, Bartolini S, Giangaspero F, Brandes AA. Effect of grade on survival in IDH-mutant grade II and grade III gliomas. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.2036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2036 Background: The 2016 WHO classification dramatically changed the diagnosis of gliomas. Diffuse gliomas are classified according to the presence of IDH-mutation (IDH-mut) and the deletion of both 1p and 19q chromosome arms (1p/19q codel). Now debate is whether grade still has an independent prognostic value. The aim of this study was to find out if grade is a prognostic factor independently of molecular status. Methods: We analyzed our institutional data warehouse for all consecutive patients (pts) with newly diagnosed, histologically proven Grade II or Grade III IDH-mut gliomas. IDH 1/2 assessment by polymerase chain reaction (PCR)or immunohistochemistry (IHC) was accepted. Next Generation Sequencing (NGS) for IDH1(exon 4) and IDH2(exon 4) was performed on all specimens wild-type for the IDH. Results: The analysis included all the 399 pts who had a grade II (n = 250, 62.7%) or grade III (n = 149, 37.3%). Median follow-up time was 105.3 months. After surgery, 72 pts (18.0%) received RT alone, 44 (11.0%) received CT alone, 135 (33.8%) received both RT and CT, and 142 (35.6%) follow-up without any treatment. Median survival was 148.1 months. In multivariate analysis Grade (HR = 0.342, 95%CI: 0.221 – 0.531; P < 0.001) and 1p/19q codeletion (HR = 0.440, 95%CI: 0.290 – 0.668; P < 0.001) were independently associated with a lower risk for death. The difference in survival remained when adjusted for histological subtype. Residual disease after surgery or biopsy negatively affected survival (HR 2.151, 95%CI 1.375 – 3.367, P = 0.001). Post-surgical treatment with RT + adjuvant CT improves survival in respect to follow-up and other treatments (HR: 0.316, 95%CI 0.156 – 0.641, P = 0.001). Conclusions: Grade still affects survival in IDH mutant Grade II and III gliomas. This effect was independent onmolecular features, surgical extension and post-surgical treatments. Clinical management of gliomas should continue to take into account grade as well as molecular characteristics.
Collapse
Affiliation(s)
- Giuseppe Lamberti
- Department of Medical Oncology S.Orsola Malpighi Hospital Bologna, Bologna, Italy
| | - Enrico Franceschi
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | | | - Antonella Mura
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alexandro Paccapelo
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Maria Pia Foschini
- Unit of Anatomic Pathology at Bellaria Hospital, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Sofia Asioli
- Department of Biomedical and Neuromotor Sciences (DIBINEM)-Surgical Pathology Section- Alma Mater Studiorum - University of Bologna, Universita degli Studi di Bologna Scuola di Medicina e Chirurgia, Bologna, Italy
| | - Dario De Biase
- Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Annalisa Pession
- Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Giovanni Tallini
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, School of Medicine, Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology, Azienda USL– IRCCS Institute of Neurological Science, Bologna, Italy
| | - Felice Giangaspero
- Università La Sapienza - Rome & IRCCS Neuromed - Pozzilli, Rome & Pozzilli, Italy
| | | |
Collapse
|
22
|
Franceschi E, Tosoni A, De Biase D, Lamberti G, Danieli D, Pizzolitto S, Zunarelli E, Visani M, Di Oto E, Mura A, Minichillo S, Scafati C, Asioli S, Paccapelo A, Bartolini S, Brandes AA. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option? Oncologist 2019; 24:664-670. [PMID: 30777895 PMCID: PMC6516106 DOI: 10.1634/theoncologist.2018-0549] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 12/14/2018] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Patients with low-grade gliomas (LGGs) with isocitrate dehydrogenase (IDH) mutation (mut) and 1p19q codeletion (codel) have a median overall survival of longer than 10 years. The aim of this study is to assess the role of postsurgical treatments. SUBJECTS, MATERIALS, AND METHODS We evaluated patients with LGGs with IDH mut and 1p19q codel; IDH1/2 was performed by immunohistochemistry and quantitative polymerase chain reaction. In all wild-type cases, we performed next-generation sequencing. 1p19 codel analysis was performed by fluorescence in situ hybridization. RESULTS Among the 679 patients, 93 with LGGs with IDH mutation and 1p19q codel were included. Median follow-up (FU) was 96.1 months. Eighty-four patients (90.3%) were high risk according to Radiation Therapy Oncology Group criteria. After surgery, 50 patients (53.7%) received only FU, 17 (18.3%) chemotherapy (CT), and 26 (30.1%) radiotherapy (RT) with (RT + CT, 8 patients, 8.6%) or without (RT, 18 patients, 19.4%) chemotherapy. Median progression-free survival (mPFS) was 46.3 months, 50.8 months, 103.6 months, and 120.2 months in patients with FU alone, with CT alone, with RT alone, or with RT + CT, respectively. Median PFS was significantly longer in patients who received postsurgical treatment (79.5 months, 95% confidence interval [CI]: 66.4-92.7) than patients who received FU (46.3 months, 95% CI: 36.0-56.5). Moreover, mPFS was longer in patients who received RT (alone or in combination with CT, n = 26, 113.8 months, 95% CI: 57.2-170.5) than those who did not (n = 67, 47.3 months, 95% CI: 36.4-58.2). In particular, temozolomide alone did not improve PFS with respect to FU. CONCLUSION RT with or without chemotherapy, but not temozolomide alone, could extend PFS in IDH mut 1p19q codel LGGs. IMPLICATIONS FOR PRACTICE Low-grade gliomas with high-risk features, defined according to Radiation Therapy Oncology Group criteria, receive radiotherapy and/or chemotherapy as postsurgical treatments. Radiotherapy, however, has serious long-term effects (cognitive impairment), which are to be taken into account in these young patients. Moreover, low-grade gliomas with isocitrate dehydrogenase mutation and 1p19q codeletion (oligodendrogliomas) have an extremely long survival and a better prognosis. This study suggests that postsurgical treatments prolong the time before tumor progression in patients with good prognosis as well as those with oligodendroglioma. Moreover, temozolomide alone might not be effective in prolonging progression-free survival.
Collapse
Affiliation(s)
- Enrico Franceschi
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alicia Tosoni
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Dario De Biase
- Department of Pharmacy and Biotechnology - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Giuseppe Lamberti
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Daniela Danieli
- Department of Pathology, San Bortolo Hospital, Vicenza, Italy
| | - Stefano Pizzolitto
- Department of Pathology, Santa Maria della Misericordia Hospital, Udine, Italy
| | | | - Michela Visani
- Department of Experimental, Diagnostic and Specialty Medicine - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Enrico Di Oto
- Department of Biomedical and Neuromotor Sciences, Section of Anatomic Pathology, University of Bologna, Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Santino Minichillo
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Chiara Scafati
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Sofia Asioli
- Department of Biomedical and Neuromotor Sciences, Surgical Pathology Section, University of Bologna, Bologna, Italy
| | - Alexandro Paccapelo
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alba A Brandes
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| |
Collapse
|
23
|
Mura A, Adriani A, Connerney JEP, Bolton S, Altieri F, Bagenal F, Bonfond B, Dinelli BM, Gérard JC, Greathouse T, Grodent D, Levin S, Mauk B, Moriconi ML, Saur J, Waite JH, Amoroso M, Cicchetti A, Fabiano F, Filacchione G, Grassi D, Migliorini A, Noschese R, Olivieri A, Piccioni G, Plainaki C, Sindoni G, Sordini R, Tosi F, Turrini D. Juno observations of spot structures and a split tail in Io-induced aurorae on Jupiter. Science 2018; 361:774-777. [PMID: 29976795 DOI: 10.1126/science.aat1450] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Accepted: 06/15/2018] [Indexed: 11/02/2022]
Abstract
Jupiter's aurorae are produced in its upper atmosphere when incoming high-energy electrons precipitate along the planet's magnetic field lines. A northern and a southern main auroral oval are visible, surrounded by small emission features associated with the Galilean moons. We present infrared observations, obtained with the Juno spacecraft, showing that in the case of Io, this emission exhibits a swirling pattern that is similar in appearance to a von Kármán vortex street. Well downstream of the main auroral spots, the extended tail is split in two. Both of Ganymede's footprints also appear as a pair of emission features, which may provide a remote measure of Ganymede's magnetosphere. These features suggest that the magnetohydrodynamic interaction between Jupiter and its moon is more complex than previously anticipated.
Collapse
Affiliation(s)
- A Mura
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy.
| | - A Adriani
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| | - J E P Connerney
- Space Research Corporation, Annapolis, MD, USA.,NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - S Bolton
- Southwest Research Institute, San Antonio, TX, USA
| | - F Altieri
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| | - F Bagenal
- Laboratory for Atmospheric and Space Physics, University of Colorado Boulder, Boulder, CO, USA
| | - B Bonfond
- Space Science, Technologies and Astrophysical Research Institute, Laboratory for Planetary and Atmospheric Physics, University of Liège, Liège, Belgium
| | - B M Dinelli
- Institute of Atmospheric Sciences and Climate, National Research Council, Italy
| | - J-C Gérard
- Space Science, Technologies and Astrophysical Research Institute, Laboratory for Planetary and Atmospheric Physics, University of Liège, Liège, Belgium
| | - T Greathouse
- Southwest Research Institute, San Antonio, TX, USA
| | - D Grodent
- Space Science, Technologies and Astrophysical Research Institute, Laboratory for Planetary and Atmospheric Physics, University of Liège, Liège, Belgium
| | - S Levin
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - B Mauk
- Applied Physics Laboratory, Johns Hopkins University, Laurel, MD, USA
| | - M L Moriconi
- Institute of Atmospheric Sciences and Climate, National Research Council, Italy
| | - J Saur
- Institut für Geophysik und Meteorologie, University of Cologne, Köln, Germany
| | - J H Waite
- Southwest Research Institute, San Antonio, TX, USA.,Department of Physics and Astronomy, University of Texas at San Antonio, San Antonio, TX, USA
| | - M Amoroso
- Agenzia Spaziale Italiana, Rome, Italy
| | - A Cicchetti
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| | - F Fabiano
- Institute of Atmospheric Sciences and Climate, National Research Council, Italy
| | - G Filacchione
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| | - D Grassi
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| | - A Migliorini
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| | - R Noschese
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| | | | - G Piccioni
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| | - C Plainaki
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy.,Agenzia Spaziale Italiana, Rome, Italy
| | - G Sindoni
- Agenzia Spaziale Italiana, Rome, Italy
| | - R Sordini
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| | - F Tosi
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| | - D Turrini
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, Italy
| |
Collapse
|
24
|
Franceschi E, Mura A, De Biase D, Tallini G, Pession A, Foschini MP, Danieli D, Pizzolitto S, Zunarelli E, Lanza G, Bartolini D, Silini EM, Visani M, Di Oto E, Tosoni A, Minichillo S, Lamberti G, Lanese A, Paccapelo A, Bartolini S, Brandes AA. The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival? Future Oncol 2018; 14:1559-1567. [PMID: 29938525 DOI: 10.2217/fon-2017-0634] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
AIM To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) and to correlate with survival. METHODS We reviewed records from adult LGG patients from 1991 to 2015 who received surgery and had sufficient tissue to molecular biomarkers characterization. RESULTS 213 consecutive LGG patients were included: 17.4% were low-risk, according to Radiation Therapy Oncology Group (RTOG) risk assessment. IDH 1/2 mutation, 1p/19q co-deletion, MGMT methylation were found in 93, 50.8 and 65.3% of patients. Median follow-up was 98.3 months. In univariate analysis, overall survival was influenced by extent of resection (p = 0.011), IDH mutation (p < 0.001), 1p/19q co-deletion (p = 0.015) and MGMT methylation (p = 0.013). In multivariate analysis, RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. RTOG clinical risk (p = 0.006), IDH mutation (p < 0.001) and 1p/19q co-deletion (p = 0.035) correlated with overall survival. CONCLUSION Both clinical and molecular factors are essential to determine prognosis and treatment strategies.
Collapse
Affiliation(s)
- Enrico Franceschi
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Dario De Biase
- Department of Pharmacy and Biotechnology (FaBiT), Molecular Diagnostic Unit AUSL ofBologna, University of Bologna, Bologna, Italy
| | - Giovanni Tallini
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy
| | - Annalisa Pession
- Department of Pharmacy and Biotechnology (FaBiT), Molecular Diagnostic Unit AUSL ofBologna, University of Bologna, Bologna, Italy
| | - Maria Pia Foschini
- Department of Biomedical & Neuro Motor Sciences, Anatomic Pathology 'M Malpighi' at Bellaria Hospital, University of Bologna, Bologna, Italy
| | - Daniela Danieli
- Department of Pathology, San Bortolo Hospital, Vicenza, Italy
| | - Stefano Pizzolitto
- Department of Pathology, Santa Maria della Misericordia Hospital, Udine, Italy
| | | | - Giovanni Lanza
- Department of Pathology, S Anna University Hospital & University of Ferrara, Ferrara, Italy
| | | | - Enrico Maria Silini
- Department of Pathology, University Hospital of Parma, Via Gramsci 14, 43100, Parma, Italy
| | - Michela Visani
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy
| | - Enrico Di Oto
- Section of Anatomic Pathology, Department of Biomedical & Neuromotor Sciences, University of Bologna, 40139, Bologna, Italy
| | - Alicia Tosoni
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Santino Minichillo
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Giuseppe Lamberti
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Andrea Lanese
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alexandro Paccapelo
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alba A Brandes
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| |
Collapse
|
25
|
Franceschi E, Mura A, Paccapelo A, Bartolini S, Minichillo S, Lanese A, Agati R, Balestrini D, Currà MF, Scafati C, Visani M, Di Battista M, Lombardo L, Genestreti G, Brandes AA. Concordance between RTOG and EORTC risk factors in low grade gliomas: Who will remain standing in the ring at bell’s sound? J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.2040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Enrico Franceschi
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alexandro Paccapelo
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology, Azienda USL– IRCCS Institute of Neurological Science, Bologna, Italy
| | - Santino Minichillo
- Department of Medical Oncology, Azienda USL– IRCCS Institute of Neurological Science, Bologna, Italy
| | - Andrea Lanese
- Department of Medical Oncology Bellaria Hospital Bologna, Bologna, Italy
| | - Raffaele Agati
- Neuroradiology Department, IRCCS of Neurological Sciences,Bellaria Hospital, Bologna, Italy
| | | | | | | | - Michela Visani
- Department of Pathology Bellaria Hospital, Bologna, Italy
| | - Monica Di Battista
- Medical Oncology Department, Bellaria-Maggiore Hospital, Azienda USL of Bologna - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Laura Lombardo
- Medical Oncology Department, Bellaria-Maggiore Hospital, Azienda USL of Bologna, Bologna, Italy
| | - Giovenzio Genestreti
- Medical Oncology Department, Bellaria-Maggiore Hospital, Azienda USL of Bologna - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alba Ariela Brandes
- Medical Oncology Department, Bellaria Hospital, AUSL-IRCCS Institute of Neurological Sciences, Bologna, Italy
| |
Collapse
|
26
|
Franceschi E, Lamberti G, Paccapelo A, Bartolini S, Minichillo S, Mura A, Tallini G, Pession A, De Biase D, Agati R, Scafati C, Currà MF, Di Battista M, Lombardo L, Genestreti G, Visani M, Brandes AA. Third-line therapy in glioblastoma: Analysis of a single centre database. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e14057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Enrico Franceschi
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Giuseppe Lamberti
- Department of Medical Oncology S.Orsola Malpighi Hospital Bologna, Bologna, Italy
| | - Alexandro Paccapelo
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology, Azienda USL– IRCCS Institute of Neurological Science, Bologna, Italy
| | - Santino Minichillo
- Department of Medical Oncology, Azienda USL– IRCCS Institute of Neurological Science, Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Giovanni Tallini
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, School of Medicine, Bologna, Italy
| | - Annalisa Pession
- Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Dario De Biase
- Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Raffaele Agati
- Neuroradiology Department, IRCCS of Neurological Sciences,Bellaria Hospital, Bologna, Italy
| | | | | | - Monica Di Battista
- Medical Oncology Department, Bellaria-Maggiore Hospital, Azienda USL of Bologna - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Laura Lombardo
- Medical Oncology Department, Bellaria-Maggiore Hospital, Azienda USL of Bologna, Bologna, Italy
| | - Giovenzio Genestreti
- Medical Oncology Department, Bellaria-Maggiore Hospital, Azienda USL of Bologna - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Michela Visani
- Department of Pathology Bellaria Hospital, Bologna, Italy
| | | |
Collapse
|
27
|
Franceschi E, Lamberti G, Visani M, Paccapelo A, Mura A, Tallini G, Pession A, De Biase D, Minichillo S, Tosoni A, Di Battista M, Cubeddu A, Bartolini S, Brandes AA. Temozolomide rechallenge in recurrent glioblastoma: when is it useful? Future Oncol 2018; 14:1063-1069. [PMID: 29741106 DOI: 10.2217/fon-2017-0681] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
AIM To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent with and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression. METHODS We retrospectively evaluated 106 glioblastoma patients who had nonprogressive disease at first magnetic resonance imaging after completion of TMZ concurrent with and adjuvant to radiotherapy, a treatment-free interval (TFI) of at least 8 weeks and received TMZ rechallenge or a nitrosourea at the time of progression. RESULTS In patients with TFI ≥5 months, median survival was 17.7 and 11.6 months and median progression-free survival was 8.1 and 5.8 months in the TMZ and nitrosourea group, respectively. Longer TFI was associated with reduced risk for death (p = 0.002) and for disease progression (p = 0.005). CONCLUSION TFI ≥5 months represents a predictor of retained TMZ sensitivity.
Collapse
Affiliation(s)
- Enrico Franceschi
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Giuseppe Lamberti
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Michela Visani
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy
| | - Alexandro Paccapelo
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Giovanni Tallini
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy
| | - Annalisa Pession
- Department of Pharmacy & Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Dario De Biase
- Department of Pharmacy & Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Santino Minichillo
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alicia Tosoni
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Monica Di Battista
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alessio Cubeddu
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Alba A Brandes
- Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy
| |
Collapse
|
28
|
Lentini A, Mura A, Muscas E, Nuvoli MT, Cocco A. Effects of delayed mating on the reproductive biology of the vine mealybug, Planococcus ficus (Hemiptera: Pseudococcidae). Bull Entomol Res 2018; 108:263-270. [PMID: 28803567 DOI: 10.1017/s000748531700075x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The effect of increasing mating delay on the reproductive performance and population growth rates of the vine mealybug, Planococcus ficus (Signoret) (Hemiptera: Pseudococcidae), was investigated under laboratory conditions. Virgin females were mated at 1, 3, 5, 7, 14, 21 and 28 days after emergence and reproductive and life table parameters were estimated. The pre-oviposition period (number of days between mating and the onset of oviposition) significantly decreased in females mated within 7 days, whereas females mated at older ages showed equivalent pre-oviposition periods (7 days, as shorter delays in mating did not reduce the population growth rates.
Collapse
Affiliation(s)
- A Lentini
- Dipartimento di Agraria,Sezione di Patologia Vegetale ed Entomologia,University of Sassari,Viale Italia 39,07100 Sassari,Italy
| | - A Mura
- Dipartimento di Agraria,Sezione di Patologia Vegetale ed Entomologia,University of Sassari,Viale Italia 39,07100 Sassari,Italy
| | - E Muscas
- Dipartimento di Agraria,Sezione di Patologia Vegetale ed Entomologia,University of Sassari,Viale Italia 39,07100 Sassari,Italy
| | - M T Nuvoli
- Dipartimento di Agraria,Sezione di Patologia Vegetale ed Entomologia,University of Sassari,Viale Italia 39,07100 Sassari,Italy
| | - A Cocco
- Dipartimento di Agraria,Sezione di Patologia Vegetale ed Entomologia,University of Sassari,Viale Italia 39,07100 Sassari,Italy
| |
Collapse
|
29
|
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F, Agostara B, Aieta M, Alabiso O, Alicicco MG, Amadori D, Amaducci L, Amiconi G, Antuzzi G, Ardine M, Ardizzoia A, Aversa C, Badalamenti G, Barni S, Basurto C, Berardi R, Bergamasco C, Bidoli P, Bighin C, Biondi E, Bisagni G, Boni C, Borgonovo K, Botta M, Bravi S, Bruzzi P, Buono G, Butera A, Caldara A, Candeloro G, Cappelletti C, Cardalesi C, Carfora E, Cariello A, Carrozza F, Cartenì G, Caruso M, Casadei V, Casanova C, Castori L, Cavanna L, Cavazzini G, Cazzaniga M, Chilelli M, Chiodini P, Chiorrini S, Ciardiello F, Ciccarese M, Cinieri S, Clerico M, Coccaro M, Comande M, Corbo C, Cortino G, Cusenza S, Daniele G, D'arco AM, D'auria G, Dazzi C, De Angelis C, de Braud F, De Feo G, De Matteis A, De Tursi M, Di Blasio A, di Lucca G, Di Lullo L, Di Rella F, Di Renzo G, Di Stefano P, Di Stefano A, Diana A, Donati S, Fabbri A, Fabi A, Faedi M, Farina G, Farris A, Febbraro A, Fedele P, Federico P, Ferraù F, Ferretti G, Ferro A, Floriani I, Forcignanò R, Forciniti S, Forestieri V, Fornari G, Frisinghelli M, Fusco V, Gallizzi G, Galvano A, Gambardella A, Gambi A, Gebbia V, Gervasi E, Ghilardi M, Giacobino A, Giardina G, Giotta F, Giraudi S, Giuliano M, Grassadonia A, Grasso D, Grosso F, Guizzaro L, Incoronato P, Incorvaia L, Iodice G, La Verde N, Labonia V, Landi G, Latorre A, Leonardi V, Levaggi A, Limite G, Lina Bascialla L, Livi L, Maiello E, Mandelli D, Marcon I, Menon D, Montedoro M, Moraca L, Moretti A, Morritti MG, Morselli P, Mura A, Mura S, Musacchio M, Muzio A, Natale D, Natoli C, Nigro C, Nisticò C, Nuzzo A, Orditura M, Orlando L, Pacilio C, Palumbo G, Palumbo R, Pasini F, Paterno E, Pazzola A, Pelliccioni S, Pensabene M, Perroni D, Pesenti Gritti A, Petrelli F, Piccirillo MC, Pinotti G, Pogliani C, Poli D, Prader S, Recchia F, Rizzi D, Romano C, Rossello R, Rossini C, Salvucci G, Sanna V, Santini A, Saracchini S, Savastano C, Scambia G, Schettini F, Schiavone P, Schirone A, Seles E, Signoriello S, Signoriello G, Silva RR, Silvestri A, Simeon V, Spagnoletti I, Tamberi S, Teragni C, Thalmann V, Thomas R, Thomas G, Tienghi A, Tinari N, Tinessa V, Tomei F, Tonini G, Torri V, Traficante D, Tudini M, Turazza M, Vignoli R, Vitale MG, Zacchia A, Zagarese P, Zanni A, Zavallone L, Zavettieri M, Zoboli A. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol 2018; 19:474-485. [PMID: 29482983 DOI: 10.1016/s1470-2045(18)30116-5] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Revised: 01/04/2018] [Accepted: 01/08/2018] [Indexed: 01/04/2023]
Abstract
BACKGROUND Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. METHODS FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). Randomisation was done by a computerised minimisation procedure stratified for oestrogen receptor, progesterone receptor, and HER2 status; previous chemotherapy; and pathological nodal status. Neither the patients nor the physicians were masked to treatment allocation. The primary endpoint was disease-free survival. The minimum cutoff to declare superiority of the upfront strategy over the switch strategy was assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacy analyses were done by intention to treat; safety analyses included all patients for whom at least one safety case report form had been completed. Follow-up is ongoing. This trial is registered with the European Clinical Trials Database, number 2006-004018-42, and ClinicalTrials.gov, number NCT00541086. FINDINGS Between March 9, 2007, and July 31, 2012, 3697 patients were enrolled into the study. After a median follow-up of 60 months (IQR 46-72), 401 disease-free survival events were reported, including 211 (11%) of 1850 patients allocated to the switch strategy and 190 (10%) of 1847 patients allocated to upfront treatment. 5-year disease-free survival was 88·5% (95% CI 86·7-90·0) with the switch strategy and 89·8% (88·2-91·2) with upfront treatment (hazard ratio 0·89, 95% CI 0·73-1·08; p=0·23). 5-year disease-free survival was 90·0% (95% CI 87·9-91·7) with anastrozole (124 events), 88·0% (85·8-89·9) with exemestane (148 events), and 89·4% (87·3 to 91·1) with letrozole (129 events; p=0·24). No unexpected serious adverse reactions or treatment-related deaths occurred. Musculoskeletal side-effects were the most frequent grade 3-4 events, reported in 130 (7%) of 1761 patients who received the switch strategy and 128 (7%) of 1766 patients who received upfront treatment. Grade 1 musculoskeletal events were more frequent with the upfront schedule than with the switch schedule (924 [52%] of 1766 patients vs 745 [42%] of 1761 patients). All other grade 3-4 adverse events occurred in less than 2% of patients in either group. INTERPRETATION 5 years of treatment with aromatase inhibitors was not superior to 2 years of tamoxifen followed by 3 years of aromatase inhibitors. None of the three aromatase inhibitors was superior to the others in terms of efficacy. Therefore, patient preference, tolerability, and financial constraints should be considered when deciding the optimal treatment approach in this setting. FUNDING Italian Drug Agency.
Collapse
Affiliation(s)
- Sabino De Placido
- Dipartimento di Clinica Medica e Chirurgia, Università Federico II, Naples, Italy
| | - Ciro Gallo
- Statistica Medica, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy
| | - Michelino De Laurentiis
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Pascale, Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy
| | - Giancarlo Bisagni
- Dipartimento di Oncologia, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
| | - Grazia Arpino
- Dipartimento di Clinica Medica e Chirurgia, Università Federico II, Naples, Italy
| | | | | | - Antonio Russo
- Dipartimento di Scienze Chirurgiche, Oncologiche e Stomatologiche, Sezione di Oncologia Medica, Università di Palermo, Palermo, Italy
| | - Lucia Del Mastro
- Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova-Oncologia Medica, Ospedale Policlinico San Martino, Genoa, Italy
| | | | - Francesco Cognetti
- Divisione Oncologia Medica 1, Istituto Nazionale Tumori Regina Elena, Rome, Italy
| | - Stefania Gori
- Oncologia Medica, Ospedale Sacro Cuore Don Calabria, Negrar, Italy
| | | | | | - Domenico Amoroso
- Oncologia Medica, Ospedale della Versilia, Lido di Camaiore (LU), Istituto Toscano Tumori, Florence, Italy
| | | | - Luca Moscetti
- Dipartimento di Oncologia Medica, Ospedale Belcolle, Viterbo, Italy
| | - Filippo Montemurro
- Divisione di Oncologia Clinica Investigativa dell'Istituto di Candiolo-IRCCS, Candiolo, Italy
| | | | | | - Vito Lorusso
- Polo Oncologico, Ospedale Vito Fazzi, Lecce, Italy
| | - Adriano Gravina
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Pascale, Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy
| | - Gabriella Moretti
- Dipartimento di Oncologia, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
| | - Rossella Lauria
- Dipartimento di Clinica Medica e Chirurgia, Università Federico II, Naples, Italy
| | - Antonella Lai
- Oncologia Medica, Azienda Ospedaliera Universitaria, Sassari, Italy
| | | | - Sergio Rizzo
- Dipartimento di Scienze Chirurgiche, Oncologiche e Stomatologiche, Sezione di Oncologia Medica, Università di Palermo, Palermo, Italy
| | - Francesco Nuzzo
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Pascale, Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy
| | - Paolo Carlini
- Divisione Oncologia Medica 1, Istituto Nazionale Tumori Regina Elena, Rome, Italy
| | - Francesco Perrone
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Pascale, Istituto di Ricovero e Cura a Carattere Scientifico, Naples, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Connerney JEP, Adriani A, Allegrini F, Bagenal F, Bolton SJ, Bonfond B, Cowley SWH, Gerard JC, Gladstone GR, Grodent D, Hospodarsky G, Jorgensen JL, Kurth WS, Levin SM, Mauk B, McComas DJ, Mura A, Paranicas C, Smith EJ, Thorne RM, Valek P, Waite J. Jupiter's magnetosphere and aurorae observed by the Juno spacecraft during its first polar orbits. Science 2018; 356:826-832. [PMID: 28546207 DOI: 10.1126/science.aam5928] [Citation(s) in RCA: 94] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Accepted: 04/20/2017] [Indexed: 11/02/2022]
Abstract
The Juno spacecraft acquired direct observations of the jovian magnetosphere and auroral emissions from a vantage point above the poles. Juno's capture orbit spanned the jovian magnetosphere from bow shock to the planet, providing magnetic field, charged particle, and wave phenomena context for Juno's passage over the poles and traverse of Jupiter's hazardous inner radiation belts. Juno's energetic particle and plasma detectors measured electrons precipitating in the polar regions, exciting intense aurorae, observed simultaneously by the ultraviolet and infrared imaging spectrographs. Juno transited beneath the most intense parts of the radiation belts, passed about 4000 kilometers above the cloud tops at closest approach, well inside the jovian rings, and recorded the electrical signatures of high-velocity impacts with small particles as it traversed the equator.
Collapse
Affiliation(s)
- J E P Connerney
- Space Research Corporation, Annapolis, MD 21403, USA. .,NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - A Adriani
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, 00133, Italy
| | - F Allegrini
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - F Bagenal
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO 80303, USA
| | - S J Bolton
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - B Bonfond
- Institut d'Astrophysique et de Geophysique, Universite de Liege, Liege, B-4000 Belgium
| | | | - J-C Gerard
- Institut d'Astrophysique et de Geophysique, Universite de Liege, Liege, B-4000 Belgium
| | - G R Gladstone
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - D Grodent
- Institut d'Astrophysique et de Geophysique, Universite de Liege, Liege, B-4000 Belgium
| | | | - J L Jorgensen
- National Space Institute, Technical University of Denmark, Kongens Lyngby, 2800, Denmark
| | - W S Kurth
- University of Iowa, Iowa City, IA 52242, USA
| | - S M Levin
- Jet Propulsion Laboratory/California Institute of Technology, Pasadena, CA 91109, USA
| | - B Mauk
- Johns Hopkins University, Applied Physics Laboratory, Laurel, MD 20723, USA
| | - D J McComas
- Department of Astrophysical Sciences, Princeton University, Princeton, NJ 08544, USA
| | - A Mura
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, Rome, 00133, Italy
| | - C Paranicas
- Johns Hopkins University, Applied Physics Laboratory, Laurel, MD 20723, USA
| | - E J Smith
- Jet Propulsion Laboratory/California Institute of Technology, Pasadena, CA 91109, USA
| | - R M Thorne
- Department of Atmospheric and Oceanic Sciences, University of California-Los Angeles, Los Angeles, CA 90095, USA
| | - P Valek
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - J Waite
- Southwest Research Institute, San Antonio, TX 78238, USA
| |
Collapse
|
31
|
Bolton SJ, Adriani A, Adumitroaie V, Allison M, Anderson J, Atreya S, Bloxham J, Brown S, Connerney JEP, DeJong E, Folkner W, Gautier D, Grassi D, Gulkis S, Guillot T, Hansen C, Hubbard WB, Iess L, Ingersoll A, Janssen M, Jorgensen J, Kaspi Y, Levin SM, Li C, Lunine J, Miguel Y, Mura A, Orton G, Owen T, Ravine M, Smith E, Steffes P, Stone E, Stevenson D, Thorne R, Waite J, Durante D, Ebert RW, Greathouse TK, Hue V, Parisi M, Szalay JR, Wilson R. Jupiter's interior and deep atmosphere: The initial pole-to-pole passes with the Juno spacecraft. Science 2018; 356:821-825. [PMID: 28546206 DOI: 10.1126/science.aal2108] [Citation(s) in RCA: 186] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Accepted: 05/01/2017] [Indexed: 11/02/2022]
Abstract
On 27 August 2016, the Juno spacecraft acquired science observations of Jupiter, passing less than 5000 kilometers above the equatorial cloud tops. Images of Jupiter's poles show a chaotic scene, unlike Saturn's poles. Microwave sounding reveals weather features at pressures deeper than 100 bars, dominated by an ammonia-rich, narrow low-latitude plume resembling a deeper, wider version of Earth's Hadley cell. Near-infrared mapping reveals the relative humidity within prominent downwelling regions. Juno's measured gravity field differs substantially from the last available estimate and is one order of magnitude more precise. This has implications for the distribution of heavy elements in the interior, including the existence and mass of Jupiter's core. The observed magnetic field exhibits smaller spatial variations than expected, indicative of a rich harmonic content.
Collapse
Affiliation(s)
- S J Bolton
- Southwest Research Institute, San Antonio, TX 78238, USA.
| | - A Adriani
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, 00133 Rome, Italy
| | - V Adumitroaie
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - M Allison
- Goddard Institute for Space Studies, New York, NY 10025, USA
| | - J Anderson
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - S Atreya
- University of Michigan, Ann Arbor, MI 48109, USA
| | - J Bloxham
- Harvard University, Cambridge, MA 02138, USA
| | - S Brown
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - J E P Connerney
- Space Research Corporation, Annapolis, MD 21403, USA.,NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - E DeJong
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - W Folkner
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - D Gautier
- Laboratoire d'Études Spatiales et d'Instrumentation en Astrophysique, Observatoire de Paris, 92195 Meudon, France
| | - D Grassi
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, 00133 Rome, Italy
| | - S Gulkis
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - T Guillot
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Laboratoire Lagrange CNRS, 06304 Nice, France
| | - C Hansen
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - W B Hubbard
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ 85721, USA
| | - L Iess
- Sapienza University of Rome, 00185 Rome, Italy
| | - A Ingersoll
- California Institute of Technology, Pasadena, CA 91125, USA
| | - M Janssen
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - J Jorgensen
- National Space Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
| | - Y Kaspi
- Department of Earth and Planetary Sciences, Weizmann Institute of Science, Rehovot 76100, Israel
| | - S M Levin
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - C Li
- California Institute of Technology, Pasadena, CA 91125, USA
| | - J Lunine
- Cornell University, Ithaca, NY 14853, USA
| | - Y Miguel
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Laboratoire Lagrange CNRS, 06304 Nice, France
| | - A Mura
- Institute for Space Astrophysics and Planetology, National Institute for Astrophysics, 00133 Rome, Italy
| | - G Orton
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - T Owen
- Institute for Astronomy, University of Hawaii at Manoa, Honolulu, HI 96822, USA
| | - M Ravine
- Malin Space Science Systems, San Diego, CA 92121, USA
| | - E Smith
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - P Steffes
- Center for Space Technology and Research, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | - E Stone
- California Institute of Technology, Pasadena, CA 91125, USA
| | - D Stevenson
- California Institute of Technology, Pasadena, CA 91125, USA
| | - R Thorne
- Department of Atmospheric and Oceanic Sciences, University of California, Los Angeles, CA 90095, USA
| | - J Waite
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - D Durante
- Sapienza University of Rome, 00185 Rome, Italy
| | - R W Ebert
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - T K Greathouse
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - V Hue
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - M Parisi
- Jet Propulsion Laboratory/Caltech, Pasadena, CA 91109, USA
| | - J R Szalay
- Southwest Research Institute, San Antonio, TX 78238, USA
| | - R Wilson
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO 80303, USA
| |
Collapse
|
32
|
Franceschi E, De Biase D, Mura A, Paccapelo A, Tosoni A, Bartolini S, Tallini G, Pession A, Danieli D, Rossi S, Bartolini D, Gardiman MP, Volpin L, Fioravanti A, Ramponi V, Zunarelli E, Bortolotti C, Visani M, Minichillo S, Cubeddu A, Silini EM, Pizzolitto S, Brandes A. PATH-36. REPEATING TESTING IN IDH WILD TYPE LGG CASES. THE IMPORTANCE OF NEXT GENERATION SEQUENCING. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Visani M, Acquaviva G, Marucci G, Paccapelo A, Mura A, Franceschi E, Grifoni D, Pession A, Tallini G, Brandes AA, de Biase D. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. J Neurooncol 2017; 135:245-254. [PMID: 28748342 DOI: 10.1007/s11060-017-2571-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Accepted: 07/13/2017] [Indexed: 02/05/2023]
Abstract
According to the 2016 World Health Organization (WHO) classification of tumors of the central nervous system, assessment of exon 4 mutations in isocitrate dehydrogenase 1 or 2 genes (IDH1 or IDH2) is an essential step in the characterization of gliomas. The p.R132H mutation is the most frequent alteration in IDH genes, however other non-canonical IDH mutations can be identified. The aim of this study is to investigate in depth the prevalence of non-R132H IDH ("non-canonical") mutations in brain tumors classified according to the 2016 WHO scheme and their clonal distribution in neoplastic cells. A total of 288 consecutive cases of brain gliomas (grade II-IV) were analyzed for exon 4 IDH1 and IDH2 mutations. IDH1 and IDH2 analysis was performed using next generation sequencing. Non-canonical IDH mutations were identified in 13/52 (25.0%) grade II gliomas (astrocytomas: 8/31, 25.8%; oligodendrogliomas: 5/21, 23.8%) and in 5/40 (12.5%) grade III gliomas (astrocytomas: 3/25, 12.0%; oligodendrogliomas: 2/15, 13.3%). They were not identified in 196 grade IV gliomas (192 glioblastomas, 4 gliosarcomas). In the large majority (>80%) of tumors IDH mutations, both IDH1-R132H and the non-canonical ones, were present in the large majority (>80%) of neoplastic cells. Our data highlight the importance of investigating not only the IDH1-R132H mutation but also the non-canonical ones. These mutations are clonally distributed, with proportions of mutated neoplastic cells overlapping with those of p.R132H, a finding consistent with their driver role in gliomagenesis.
Collapse
Affiliation(s)
- Michela Visani
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy
| | - Giorgia Acquaviva
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy
| | - Gianluca Marucci
- Anatomic Pathology Unit, AUSL of Bologna, Via Altura 3, 40139, Bologna, Italy
- Department of Neuropathology, IRCCS Foundation Carlo Besta Neurological Institute, Milan, Italy
| | - Alexandro Paccapelo
- Department of Oncology, AUSL Bologna - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Antonella Mura
- Department of Oncology, AUSL Bologna - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Enrico Franceschi
- Department of Oncology, AUSL Bologna - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Daniela Grifoni
- Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Annalisa Pession
- Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Giovanni Tallini
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bologna, Italy.
- Anatomia Patologica, ASL Bologna, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Scuola di Medicina e Chirurgia, Università di Bologna, Via Altura 3, 40139, Bologna, Italy.
| | - Alba A Brandes
- Department of Oncology, AUSL Bologna - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Dario de Biase
- Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| |
Collapse
|
34
|
Mura A, Franceschi E, Minichillo S, Tosoni A, Fioravanti A, Talacchi A, Volpin L, Tallini G, De Biase D, Visani M, Degli Esposti R, Genestreti G, Pizzolitto S, Agati R, Bortolotti C, Bartolini S, Paccapelo A, Brandes A. The role of clinical and molecular characteristics in low grade gliomas. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx431.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Tosoni A, Franceschi E, Mura A, Minichillo S, Pession A, De Biase D, Danieli D, Pizzolitto S, Fioravanti A, Volpin L, Agati R, Genestreti G, Degli Esposti R, Bartolini S, Paccapelo A, Brandes A. IDH mutant and 1p19q codeleted low grade gliomas: to treat or not to treat? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx431.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Minichillo S, Franceschi E, Mura A, Tosoni A, Tallini G, Pession A, Foschini M, Bortolotti C, Danieli D, Talacchi A, Cirillo L, Di Battista M, Genestreti G, Bartolini S, Paccapelo A, Brandes A. The role of treatments in IDH mutant molecular astrocytomas. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx431.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Franceschi E, Mura A, Mandrioli A, Minichillo S, Tosoni A, Pession A, De Biase D, Danieli D, Pizzolitto S, Fioravanti A, Volpin L, Agati R, Bartolini S, Paccapelo A, Brandes A. Low grade glioma patients with IDH mutation and 1p19q codeletion: What to do after surgery? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx366.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Mandrioli A, Franceschi E, Minichillo S, Mura A, Tosoni A, De Biase D, Zunarelli E, Lanza G, Bartolini D, Silini E, Tallini G, Cirillo L, Bortolotti C, Danieli D, Bartolini S, Paccapelo A, Brandes A. IDH wild type low grade gliomas: Who seeks shall find. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx366.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Mura A, Franceschi E, Minichillo S, Mandrioli A, Tosoni A, Fioravanti A, Talacchi A, Volpin L, Tallini G, De Biase D, Agati R, Pizzolitto S, Bartolini S, Paccapelo A, Brandes A. The role of clinical characteristics in low grade gliomas in molecular era. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx366.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Minichillo S, Franceschi E, Mura A, Mandrioli A, Tosoni A, Tallini G, Pession A, Foschini M, Bortolotti C, Danieli D, Talacchi A, Cirillo L, Bartolini S, Paccapelo A, Brandes A. Prognostic factors for IDH mutant molecular astrocytomas. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx366.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Franceschi E, De Biase D, Paccapelo A, Mura A, Tosoni A, Bartolini S, Tallini G, Pession A, Danieli D, Rossi S, Bartolini D, Gardiman MP, Volpin L, Ramponi V, Fioravanti A, Foschini MP, Di Oto E, Minichillo S, Pizzolitto S, Brandes AA. Low grade glioma patients with IDH mutation and 1p19q codeletion: To treat or not to treat? J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.2017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2017 Background: Molecular characterization of low grade gliomas (LGG) is essential for diagnosis and treatment of these diseases. LGG patients (pts) with IDH mutation and 1p19q codeletion (codel) are characterized by a median OS (mOS) longer than 10 years. Thus, the role of treatments and side effects should be carefully evaluated. Methods: We evaluated LGG pts from our data warehouse (n=679 pts) who received surgery and had sufficient tissue to assess biomarkers characterization. Pts with gliomatosis were excluded. IDH1/2 assessment was performed on formalin-fixed paraffin-embedded samples by qPCR. In wild type cases we performed NGS. 1p/19 codel analysis was performed by FISH. Results: 93 consecutive LGG with IDH mutation and codel were included. The median follow up (FU) was 96.1 months. Mean age was 40 yrs (range: 25-66); 8 pts (8.6%) underwent biopsy, 61 pts (65.6%) partial resection, 24 pts (25.8%) complete resection. 84 pts (90.3%) were considered high risk using RTOG criteria (>40 years and/or incomplete resection). Fifty pts (53.7%) received only FU, 17 pts (18.3%) received chemotherapy (CT), 18 pts (19.4%) received radiotherapy (RT), 8 pts (8.6%) received RT + CT. Median PFS (mPFS) was 59.6 months (95%CI: 41.8-77.4) and was significantly longer in pts who received postsurgical treatments (79.5 months, 95%CI: 66.4-92.7) than pts who received FU (46.3 months, 95%CI: 36.0-56.5; P=0.001). mPFS was 50.8 months (95%CI: 17.4-84.3), 103.6 months (95%CI: 11.7-195.6) and 120.2 months (95%CI: 40.5-199.8) in pts treated with CT alone, RT alone and RT + CT, respectively. Multivariate analysis showed that receiving a post-surgical treatment (P<0.001), and the extent of resection (P=0.043) were significantly correlated with PFS. Conclusions: Our study evaluated the role of treatments in LGG pts assessed with NGS and FISH. Post-surgical treatments are crucial to extend PFS in pts with IDH mutation and codel. The choice of post-surgical treatments seems to have a role, being CT alone less effective than RT and RT+CT. Longer FU is needed to provide information about OS.
Collapse
Affiliation(s)
- Enrico Franceschi
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Dario De Biase
- Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | - Alexandro Paccapelo
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Antonella Mura
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | | | - Stefania Bartolini
- Department of Medical Oncology, Azienda USL– IRCCS Institute of Neurological Science, Bologna, Italy
| | - Giovanni Tallini
- Department of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, School of Medicine, Bologna, Italy
| | - Annalisa Pession
- Department of Pharmacy and Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy
| | | | - Sabrina Rossi
- Pathology Department Azienda ULSS 9 - Treviso Ospedale Generale di Treviso, Treviso, Italy
| | | | - Marina Paola Gardiman
- Pathology Department, Neurological Sciences, Azienda Ospedale–University of Padua, Padua, Italy
| | - Lorenzo Volpin
- Department of Neuroscience and Neurosurgery, San Bortolo Hospital, Vicenza, Italy
| | - Vania Ramponi
- Neurochirurgic Department Bellaria Hospital, Bologna, Italy
| | - Antonio Fioravanti
- Department of Neurosurgery Azienda USL– IRCCS Institute of Neurological Science, Bologna, Italy
| | - Maria Pia Foschini
- Unit of Anatomic Pathology at Bellaria Hospital, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
| | - Enrico Di Oto
- Pathology Department, Bellaria Hospital, Bologna, Italy
| | - Santino Minichillo
- Department of Medical Oncology, Azienda USL– IRCCS Institute of Neurological Science, Bologna, Italy
| | | | - Alba Ariela Brandes
- Medical Oncology Department, Bellaria Hospital, AUSL-IRCCS Institute of Neurological Sciences, Bologna, Italy
| |
Collapse
|
42
|
Franceschi E, De Biase D, Paccapelo A, Reni M, Mura A, Tallini G, Bortolotti C, Volpin L, Marucci G, Cirillo L, Pession A, Ghimenton C, Poggi R, Bartolini S, Albini Riccioli L, Tosoni A, Degli Esposti C, Danieli D, Genestreti G, Brandes A. Clinical risk or molecular risk: What matters in low grade gliomas? A study from the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Franceschi E, De Biase D, Poggi R, Bartolini S, Fioravanti A, Bacci A, Zucchelli M, Zunarelli E, Depenni R, Di Battista M, Crisi G, Pizzolitto S, Pasini G, Dazzi C, Gamboni A, Mura A, Brandes A. The role of clinical risk in Low Grade Glioma patients in the era of genomic medicine: a GICNO study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Brandes AA, Paccapelo A, De Biase D, Reni M, Mura A, Bartolini S, Sturiale C, Volpin L, Marucci G, Agati R, Pession A, Ghimenton C, Zunarelli E, Urbini B, Depenni R, Tosoni A, Crisi G, Pizzolitto S, Danieli D, Franceschi E. The role of clinical characteristics and molecular biomarkers in low grade gliomas (LGG): A GICNO study. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.2032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Alexandro Paccapelo
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Science, Bologna, Italy
| | - Dario De Biase
- Department of Pharmacy and Biotechnology (FaBiT), Molecular Biology Unit, Bellaria Hospital, University of Bologna, Bologna, Italy
| | - Michele Reni
- Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - Antonella Mura
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Stefania Bartolini
- Department of Medical Oncology, Azienda USL - IRCCS Institute of Neurological Science, Bologna, Italy
| | - Carmelo Sturiale
- Department of Neurosurgery Azienda USL - IRCCS Institute of Neurological Science, Bologna, Italy
| | - Lorenzo Volpin
- Department of Neuroscience and Neurosurgery, San Bortolo Hospital, Vicenza, Italy
| | - Gianluca Marucci
- Department of Biomedical and NeuroMotor Sciences (DiBiNeM), University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital, Bologna, Italy
| | - Raffaele Agati
- Neuroradiology Department, IRCCS of Neurological Sciences,Bellaria Hospital, Bologna, Italy
| | - Annalisa Pession
- Department of Biomedical and NeuroMotor Sciences (DiBiNeM), University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital, Bologna, Italy
| | - Claudio Ghimenton
- Department of Pathology and Diagnostics Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - Elena Zunarelli
- Pathology Department, Azienda Ospedaliero-Universitaria, Policlinico, Modena, Italy
| | - Benedetta Urbini
- Clinical Oncology Unit, St Anna University Hospital, Ferrara, Italy
| | - Roberta Depenni
- Oncology, Haematology and Respiratory Diseases Department, University Hospital of Modena, Modena, Italy
| | - Alicia Tosoni
- Medical Oncology Department, Bellaria-Maggiore Hospital, Azienda USL of Bologna - IRCCS Institute of Neurological Sciences, Bologna, Italy
| | - Girolamo Crisi
- Department of Neuroradiology, Azienda Ospedaliero-Universitaria, Parma, Italy
| | | | | | - Enrico Franceschi
- Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
| |
Collapse
|
45
|
Clivati C, Bolognini G, Calonico D, Faralli S, Mura A, Levi F. In-field Raman amplification on coherent optical fiber links for frequency metrology. Opt Express 2015; 23:10604-10615. [PMID: 25969100 DOI: 10.1364/oe.23.010604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Distributed Raman amplification (DRA) is widely exploited for the transmission of broadband, modulated signals used in data links, but not yet in coherent optical links for frequency metrology, where the requirements are rather different. After preliminary tests on fiber spools, in this paper we deeper investigate Raman amplification on deployed in-field optical metrological links. We actually test a Doppler-stabilized optical link both on a 94 km-long metro-network implementation with multiplexed ITU data channels and on a 180 km-long dedicated fiber haul connecting two cities, where DRA is employed in combination with Erbium-doped fiber amplification (EDFA). The performance of DRA is detailed in both experiments, indicating that it does not introduce noticeable penalties for the metrological signal or for the ITU data channels. We hence show that Raman amplification of metrological signals can be compatible with a wavelength division multiplexing architecture and that it can be used as an alternative or in combination with dedicated bidirectional EDFAs. No deterioration is noticed in the coherence properties of the delivered signal, which attains frequency instability at the 10(-19) level in both cases. This study can be of interest also in view of the undergoing deployment of continental fiber networks for frequency metrology.
Collapse
|
46
|
Calosso CE, Bertacco EK, Calonico D, Clivati C, Costanzo GA, Frittelli M, Levi F, Micalizio S, Mura A, Godone A. Doppler-stabilized fiber link with 6 dB noise improvement below the classical limit. Opt Lett 2015; 40:131-134. [PMID: 25679826 DOI: 10.1364/ol.40.000131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
It is known that temperature variations and acoustic noise affect ultrastable frequency dissemination along optical fiber. Active stabilization techniques are adopted to compensate for the fiber-induced phase noise. However, despite this compensation, the ultimate link performances are limited by the delay-unsuppressed noise that is related to the propagation delay of the light in the fiber. We demonstrate a post-processing approach which enables us to overcome this limit. We implement a subtraction algorithm between the optical signal delivered at the remote link end and the round-trip signal. In this way, a 6 dB improvement beyond the delay-unsuppressed noise is obtained. We confirm the prediction with experimental data obtained on a 47 km metropolitan fiber link and propose how to extend this method for frequency dissemination.
Collapse
|
47
|
Piras R, Aresti M, Saba M, Marongiu D, Mula G, Quochi F, Mura A, Cannas C, Mureddu M, Ardu A, Ennas G, Calzia V, Mattoni A, Musinu A, Bongiovanni G. Colloidal synthesis and characterization of Bi2S3nanoparticles for photovoltaic applications. ACTA ACUST UNITED AC 2014. [DOI: 10.1088/1742-6596/566/1/012017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
48
|
Cagetti MG, Carta G, Cocco F, Sale S, Congiu G, Mura A, Strohmenger L, Lingström P, Campus G. Effect of Fluoridated Sealants on Adjacent Tooth Surfaces: A 30-mo Randomized Clinical Trial. J Dent Res 2014; 93:59S-65S. [PMID: 24846910 DOI: 10.1177/0022034514535808] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
A double-blind randomized clinical trial was performed in 6- to 7-yr-old schoolchildren to evaluate, in a 30-mo period, whether the caries increment on the distal surface of the second primary molars adjacent to permanent first molars sealed with fluoride release compounds would be lower with respect to those adjacent to permanent first molars sealed with a nonfluoridated sealant. In sum, 2,776 subjects were enrolled and randomly divided into 3 groups receiving sealants on sound first molars: high-viscosity glass ionomer cement (GIC group); resin-based sealant with fluoride (fluoride-RB group); and a resin-based sealant without fluoride (RB group). Caries (D1 - D3 level) was recorded on the distal surface of the second primary molar, considered the unit of analysis including only sound surfaces at the baseline. At baseline, no differences in caries prevalence were recorded in the 3 groups regarding the considered surfaces. At follow-up, the prevalence of an affected unit of analysis was statistically lower (p = .03) in the GIC and fluoride-RB groups (p = .04). In the GIC group, fewer new caries were observed in the unit of analysis respect to the other 2 groups. Incidence rate ratios (IRRs) were 0.70 (95% confidence interval: 0.50, 0.86; p < .01) for GIC vs. RB and 0.79 (95% confidence interval: 0.67, 0.89; p = .005) for fluoride-RB vs. RB [Corrected]. Caries incidence was significantly associated with low socioeconomic status (IRR = 1.18; 95% confidence interval: 1.10, 1.42; p = .05). Dental sealant high-viscosity GIC and fluoride-RB demonstrated protection against dental caries, and there was evidence that these materials afforded additional protection for the tooth nearest to the sealed tooth (clinical trial registration NCT01588210).
Collapse
Affiliation(s)
- M G Cagetti
- WHO Collaborating Centre of Milan for Epidemiology and Community Dentistry, University of Milan, San Paolo Hospital, Milan, Italy
| | - G Carta
- Department of Surgery, Microsurgery, and Medical Science, School of Dentistry, University of Sassari, Italy
| | - F Cocco
- WHO Collaborating Centre of Milan for Epidemiology and Community Dentistry, University of Milan, San Paolo Hospital, Milan, Italy Department of Chemistry, University of Sassari, Italy
| | - S Sale
- Department of Surgery, Microsurgery, and Medical Science, School of Dentistry, University of Sassari, Italy
| | - G Congiu
- Department of Surgery, Microsurgery, and Medical Science, School of Dentistry, University of Sassari, Italy
| | - A Mura
- Department of Surgery, Microsurgery, and Medical Science, School of Dentistry, University of Sassari, Italy
| | - L Strohmenger
- WHO Collaborating Centre of Milan for Epidemiology and Community Dentistry, University of Milan, San Paolo Hospital, Milan, Italy
| | - P Lingström
- Department of Cariology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Sweden
| | - G Campus
- WHO Collaborating Centre of Milan for Epidemiology and Community Dentistry, University of Milan, San Paolo Hospital, Milan, Italy Department of Surgery, Microsurgery, and Medical Science, School of Dentistry, University of Sassari, Italy
| | | |
Collapse
|
49
|
Calosso CE, Bertacco E, Calonico D, Clivati C, Costanzo GA, Frittelli M, Levi F, Mura A, Godone A. Frequency transfer via a two-way optical phase comparison on a multiplexed fiber network. Opt Lett 2014; 39:1177-1180. [PMID: 24690700 DOI: 10.1364/ol.39.001177] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
We performed a two-way remote optical phase comparison on optical fiber. Two optical frequency signals were launched in opposite directions in an optical fiber and their phases were simultaneously measured at the other end. In this technique, the fiber noise is passively canceled, and we compared two optical frequencies at the ultimate 10(-21) stability level. The experiment was performed on a 47 km fiber that is part of the metropolitan network for Internet traffic. The technique relies on the synchronous measurement of the optical phases at the two ends of the link, which is here performed by digital electronics. This scheme offers some advantages with respect to active noise cancellation schemes, as the light travels only once in the fiber.
Collapse
|
50
|
Campus G, Carta G, Cagetti M, Bossù M, Sale S, Cocco F, Conti G, Nardone M, Sanna G, Strohmenger L, Lingström P, Bossù M, Campus G, Cagetti M, Caria G, Carta G, Cocco F, Congiu G, Conti G, Corridone D, Lingström P, Mastrobernardino S, Mura A, Polimeni A, Sale S, Sanna G, Strohmenger L. Fluoride Concentration from Dental Sealants. J Dent Res 2013; 92:S23-S28. [DOI: 10.1177/0022034513484329] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
Abstract
A randomized clinical trial was performed in schoolchildren (6-7 yrs) to evaluate fluoride concentration in interproximal fluid after the placement of 3 different sealants. The sample consisted of 2,776 children randomly divided: 926 in the high-viscosity Glass-ionomer Cement group (GIC group), 923 in the fluoride Resin-based group (fluoride-RB group), and 927 in the no-fluoride Resin-based group (RB group). In total, 2,640 children completed the trial. Sealants were applied following manufacturer’s instructions. Interproximal fluid samples were collected at baseline and 2, 7, and 21 days after application of sealants, by insertion of a standardized paperpoint into the interproximal mesial space of the sealed tooth for 15 seconds. Fluoride concentration was evaluated by means of a fluoride ion-selective electrode. At 2 days after sealant application, fluoride concentration was significantly higher in GIC and fluoride-RB groups compared with that in the RB group ( p < .01). Mean fluoride concentrations after 7 days were 2.54 (SE 0.68) ppm, 0.85 (SE 0.26) ppm, and 0.53 (SE 0.11) ppm for the three groups, respectively. After 21 days, fluoride concentration in the GIC group remained higher than that in the other two groups. High-viscosity GIC sealants increased the fluoride concentrations in interproximal fluid more than did a Resin-based sealant containing fluoride (ClinicalTrials.gov NCT01588210).
Collapse
Affiliation(s)
- G. Campus
- Department of Surgery, Microsurgery and Medical Science, School of Dentistry, University of Sassari, Italy
- WHO Collaborating Centre of Milan for Epidemiology and Community Dentistry, University of Milan, “S. Paolo Hospital”, Milan, Italy
| | - G. Carta
- Department of Surgery, Microsurgery and Medical Science, School of Dentistry, University of Sassari, Italy
| | - M.G. Cagetti
- WHO Collaborating Centre of Milan for Epidemiology and Community Dentistry, University of Milan, “S. Paolo Hospital”, Milan, Italy
| | - M. Bossù
- School of Dentistry, Sapienza, University of Rome, Italy
| | - S. Sale
- Department of Surgery, Microsurgery and Medical Science, School of Dentistry, University of Sassari, Italy
| | - F. Cocco
- Department of Chemistry, University of Sassari, Italy
| | - G. Conti
- WHO Collaborating Centre of Milan for Epidemiology and Community Dentistry, University of Milan, “S. Paolo Hospital”, Milan, Italy
| | - M. Nardone
- Italian Minister of Health General Office, Rome, Italy
| | - G. Sanna
- Department of Chemistry, University of Sassari, Italy
| | - L. Strohmenger
- WHO Collaborating Centre of Milan for Epidemiology and Community Dentistry, University of Milan, “S. Paolo Hospital”, Milan, Italy
| | - P. Lingström
- Department of Cariology, Institute of Odontology, The Sahlgrenska Academy, University of Gothenburg, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|